Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleSpecial Section on Bile Acids, Drug Metabolism, and Toxicity

Pregnane X Receptor and the Gut-Liver Axis: A Recent Update

Moumita Dutta, Joe Jongpyo Lim and Julia Yue Cui
Drug Metabolism and Disposition April 2022, 50 (4) 478-491; DOI: https://doi.org/10.1124/dmd.121.000415
Moumita Dutta
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Jongpyo Lim
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Yue Cui
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

It is well-known that the pregnane X receptor (PXR)/Nr1i2 is a critical xenobiotic-sensing nuclear receptor enriched in liver and intestine and is responsible for drug-drug interactions, due to its versatile ligand binding domain (LBD) and target genes involved in xenobiotic biotransformation. PXR can be modulated by various xenobiotics including pharmaceuticals, nutraceuticals, dietary factors, and environmental chemicals. Microbial metabolites such as certain secondary bile acids (BAs) and the tryptophan metabolite indole-3-propionic acid (IPA) are endogenous PXR activators. Gut microbiome is increasingly recognized as an important regulator for host xenobiotic biotransformation and intermediary metabolism. PXR regulates and is regulated by the gut-liver axis. This review summarizes recent research advancements leveraging pharmaco- and toxico-metagenomic approaches that have redefined the previous understanding of PXR. Key topics covered in this review include: (1) genome-wide investigations on novel PXR-target genes, novel PXR-DNA interaction patterns, and novel PXR-targeted intestinal bacteria; (2) key PXR-modulating activators and suppressors of exogenous and endogenous sources; (3) novel bidirectional interactions between PXR and gut microbiome under physiologic, pathophysiological, pharmacological, and toxicological conditions; and (4) modifying factors of PXR-signaling including species and sex differences and time (age, critical windows of exposure, and circadian rhythm). The review also discusses critical knowledge gaps and important future research topics centering around PXR.

SIGNIFICANCE STATEMENT This review summarizes recent research advancements leveraging O’mics approaches that have redefined the previous understanding of the xenobiotic-sensing nuclear receptor pregnane X receptor (PXR). Key topics include: (1) genome-wide investigations on novel PXR-targeted host genes and intestinal bacteria as well as novel PXR-DNA interaction patterns; (2) key PXR modulators including microbial metabolites under physiological, pathophysiological, pharmacological, and toxicological conditions; and (3) modifying factors including species, sex, and time.

Introduction

Brief Historical Perspective

Prior to the discovery of the pregnane X receptor (PXR), it was initially discovered that newborn rats exhibited higher sensitivity to nonmetabolized cardiac glycoside ouabainin in comparison with adults (Klaassen, 1972; Klaassen, 1973). This increased sensitivity was due to the lower hepatic uptake in newborns, whereas pretreatment of both newborn and adult rats with pregnenolone-16α-carbonitrile (PCN) markedly increased the hepatic uptake and biliary excretion of ouabain (Klaassen, 1974a; Klaassen, 1974b). PCN treatment in isolated rat hepatocytes markedly enhanced the uptake of another glycoside [3H] digoxin, which was a substrate of the organic anion transporter 2 (Oatp2, now known as solute carrier organic anion transporter family 1a4/Oatp1a4) (Eaton and Klaassen, 1979). It was later noted that PCN stimulated the enzyme activity of a single form of cytochrome P450 (P-450PCN) that was immunochemically distinguishable from another cytochrome P450 (CYP) inducible by phenobarbital in rat liver (P450-PB) (Newman and Guzelian, 1983). In addition, glucocorticoids such as dexamethasone could also induce P-450PCN in rat liver, and the notion of the existence of a class of microsomal enzyme inducers was proposed (Schuetz et al., 1984). These pioneer studies together supported the existence of a receptor that can be activated by chemicals such as PCN, which in turn coregulates the xenobiotic-inducible drug metabolism and transport systems (Staudinger et al., 2001).

At the turn of the century, the nuclear receptor PXR was discovered and was initially recognized as a major receptor for xenobiotics that transactivate many genes involved in drug metabolism and transport including Cyp3a (previously known as P-450PCN) and Oatp1a4 (previously known as Oatp2) (Moore and Kliewer, 2000; Kliewer et al., 2002; Tirona et al., 2003; Cheng et al., 2005; Maher et al., 2005; Kurihara et al., 2007; Petrick and Klaassen, 2007; Alnouti and Klaassen, 2008; Buckley and Klaassen, 2009; Hernandez et al., 2009; Aleksunes and Klaassen, 2012). PXR is highly expressed in the liver and intestine and can be activated by various drugs, nutraceuticals, dietary factors, and environmental chemicals (Moore et al., 2003), leading to drug-drug, food-drug, and drug-toxicant interactions. Although the DNA-binding domain of PXR is highly conserved across species (Kliewer et al., 2002), its ligand-binding domain displays more variability and versatility, which contribute to the species difference in PXR activation and target gene expression. Although being well-recognized as a classic drug-receptor over the years, studies using PXR-null and humanized PXR transgenic mice have demonstrated that PXR also contributes to intermediary metabolism through worsening diet-induced obesity, hepatic steatosis, and hepatic inflammation (Spruiell et al., 2014a; Spruiell et al., 2014b; Kim et al., 2021). However, pharmacological activation of PXR has antiinflammatory effects (Cheng et al., 2012; Huang et al., 2018). The physiologic functions of PXR have also included transactivating genes involved in lipid metabolism (Zhou et al., 2006; Zhou et al., 2008) and cell cycle (Guzelian et al., 2006).

Recent research advancements leveraging pharmaco- and toxico-metagenomic approaches have redefined our understanding of PXR. First, genome-wide investigations using chromatin immunoprecipitation coupled with second-generation sequencing have expanded the list of direct-PXR target genes and identified novel PXR-DNA interaction patterns (Cui et al., 2010; Smith et al., 2014). Although it was widely recognized based on in vitro investigations that PXR binds to AGGTCA-like direct repeats separated by 3 or 4 base pairs (DR-3 or DR-4) as well as everted repeats 6 (ER-6) and ER-8 (Kliewer et al., 2002), an in vivo roadmap of PXR bindings in mouse liver with extended search for longer response elements have identified that DR-4 is the most prevalent PXR-DNA binding motif in vivo, and more importantly, there is a novel DR-(5n+4) periodic pattern of PXR-DNA interactions (defined as an “accordion model”) (Cui et al., 2010). In addition, PXR-DNA interactions within the target gene loci are not limited to promoter regions but are also localized to regions such as distal enhancers, downstream, and introns (Cui et al., 2010). Second, although it was previously thought that PXR interacts with its binding partner retinoic X receptor (RXR) as a dimer, computational approaches have demonstrated that PXR and RXR function as a hetero-tetramer, with the unique β-stranded interface of the PXR homodimer in the middle and two RXR proteins on the outside (Noble et al., 2006; Teotico et al., 2008). In addition, the key amino acids forming the PXR homodimer interface are highly conserved during evolution, and disruption of these amino acids results in decreased transcription activity of PXR (Noble et al., 2006; Teotico et al., 2008). Third, novel endogenous PXR ligands and/or activators have been identified, which are microbial metabolites of bile acids (BAs) and tryptophan (Staudinger et al., 2001; Xie et al., 2001; Venkatesh et al., 2014). Along the same lines, novel bidirectional interactions of PXR and the gut microbiome have been discovered under physiologic, pathophysiological, pharmacological, and toxicological conditions (Cheng et al., 2018; Li et al., 2018; Dempsey et al., 2019; Scoville et al., 2019; Lim et al., 2020; Kim et al., 2021; Little et al., 2021). Last but not least, modifying factors including sex (Fu et al., 2012; Barretto et al., 2021); time, including liver development (Hart et al., 2009); early-life exposures to PXR-activating xenobiotics (Li et al., 2016a; Li et al., 2016b); aging (Fu et al., 2012); and circadian rhythm have been further elucidated. Ongoing research studies continue to expand our knowledge base regarding endogenous functions of PXR and novel target genes, novel PXR ligands/modulators, and PXR versus gut microbiome crosstalk.

This review will therefore provide an updated summary of the recent discoveries of PXR with a primary focus on PXR and the gut-liver axis within the context of exposures and discuss important further research topics in this area from our perspective.

PXR-Modulating Xenobiotics

PXR Activators

PXR is responsible for the regulation of various drug-metabolizing enzymes after activation by various ligands and/or activators (Kliewer et al., 1998). Due to its promiscuous ligand binding domain (LBD), a wide variety of possible ligands can interact with PXR and modulate complex drug-metabolizing enzymes expression through drug-drug interaction (Lehmann et al., 1998). Many synthetic drugs, natural products, environmental chemicals, as well as microbial metabolites and diets have been recognized as regulators of PXR signaling (Table 1) (Chang and Waxman, 2006). It should be noted that chemicals can only be classified as PXR ligands if the direct binding to the LBD of PXR has been established. It should also be noted that PXR-activating xenobiotics may have off-target effects that are not related to PXR signaling.

Synthetic Drugs

The antituberculosis drug rifampicin is a well-known ligand and activator of human pregnane X receptor (hPXR), which binds and activates the receptor at a relatively low concentration (Blumberg et al., 1998; Moore et al., 2000a); however, rifampicin does not activate the rodent PXR (Gibson et al., 2002). In rodents, the prototypical known PXR ligand is PCN (Marek et al., 2005; Ma et al., 2008). Cell-based reporter assays have shown that activation of hPXR by rifampicin upregulates the expression of CYP3A4 in human, rabbit, pig, dog, and rhesus monkeys (Jones et al., 2000; Moore et al., 2000; Gibson et al., 2002). In vitro ligand assays showed that hPXR binds rifampicin (Jones et al., 2000), which then triggers the release of corepressors and initiates recruitment of coactivators to promote transcription of PXR-target genes (Takeshita et al., 2002; Ourlin et al., 2003).

In addition to the prototypical ligands, many other therapeutic compounds can activate PXR either as direct ligands or indirect activators (Chang and Waxman, 2006). Dexamethasone is another PXR activator in both mice and humans (Pascussi et al., 2001; Yueh et al., 2005). The barbiturates anticonvulsant drugs, such as phenobarbital, are PXR activators in a species-specific manner. For example, phenobarbital preferably activates PXR in humans, pigs, and rabbits but has little effect in rodents including mice and rats (Jones et al., 2000; Moore and Kliewer, 2000; Smirlis et al., 2001; Wei et al., 2002; Chang and Waxman, 2006; Pinne et al., 2016). Specifically, phenobarbital enhances the recruitment of the steroid receptor coactivator-1 to hPXR but not to mouse pregnane X receptor (mPXR) (Li et al., 2019). The antifungal drug clotrimazole has been reported to bind to hPXR at a concentration of 10 µM, stimulating coactivator recruitment and enhancing the transcription of PXR target genes (Lehmann et al., 1998; Jones et al., 2000), whereas clotrimazole is a weaker activator of rat and mouse PXR (Bertilsson et al., 1998; Jones et al., 2000). The protease inhibitor and anti-HIV drug ritonavir acts as a ligand of hPXR and upregulates PXR-target gene expression in primary human hepatocyte cultures (Chang and Waxman, 2006). Cancer chemotherapeutic drugs, such as paclitaxel, activate hPXR in cell-based reporter assays (Synold et al., 2001) where it acts as an hPXR ligand and upregulates the expression of PXR-target genes including CYP3A4 and the multidrug resistance 1 (MDR1) transporter (Kostrubsky et al., 1998). The muscle relaxant etomidoline has been identified as a novel selective PXR agonist in a stable hPXR-Luc HepG2 cell line and upregulated CYP3A4 mRNA expression in HepaRG cells in a PXR-dependent manner (Lynch et al., 2021). The calcium channel blockers, such as nifedipine, bendipine, and lacidipine, are used in the treatment of high blood pressure. Studies have reported that these drugs are associated with hPXR activation (Bertilsson et al., 1998; Chang and Waxman, 2006; Lynch et al., 2021). Several other drugs including carbamazepine (El-Sankary et al., 2001; Luo et al., 2002), bosentan (van Giersbergen et al., 2002), mevastatin (Raucy et al., 2002), tamoxifen (Desai et al., 2002; Zhuo et al., 2014), and topotecan (Schuetz et al., 2002) have all been reported to be activators of hPXR in cell-based reporter gene assays. In addition, 11 additional drugs have recently been identified as novel hPXR activators (Lynch et al., 2021).

The activation of PXR by chemotherapeutic drugs can result in drug resistance and lower efficacy, partly through upregulating CYP3A4 (Chen, 2010; Mani et al., 2013). Lin et al. investigated the therapeutic value of hPXR antagonists and the expression of CYP3A4. They found that SPA70 is a potent antagonist of hPXR, which ablated the expression of CYP3A4, suggesting that SPA70 can be a potential therapeutic as an hPXR antagonist (Lin et al., 2017).

Natural Products

Several plant-derived compounds have been identified as agonists and/or activators of hPXR or mPXR in cell-based reporter assays. For example, the active ingredient of St. John’s wort, namely hyperforin, has been reported as a ligand of hPXR and the direct binding of hyperforin to the PXR ligand-binding domain has been visualized by X-ray crystallography (Watkins et al., 2003). Hyperforin upregulates the PXR-target gene CYP3A/Cyp3a expression of both human and mouse origins in cell-based reporter assays (Cantoni et al., 2003; Komoroski et al., 2004). Guggulsterones are plant-derived sterol compounds that activate hPXR and mPXR, as evidenced by increased expression of PXR-target genes (Brobst et al., 2004; Ding and Staudinger, 2005; Chang and Waxman, 2006). The plant-derived diterpene forskolin is used in traditional medicine to treat cardiovascular disorders (Seamon et al., 1981) and acts as a ligand for both hPXR and mPXR, as evidenced by increased PXR-target gene expression in cell-based reporter gene assays (Ding and Staudinger, 2005). Artemisinin, a naturally occurring sesquiterpene, is an hPXR ligand that promotes interactions between PXR and its coactivator DRIP205 (Burk et al., 2005). However, artemisinin is known to decrease the basal expression of mPXR (Burk et al., 2005). Other plant-derived compounds such as the kava extract desmethoxyyangonin and dihydromethysticin also activate hPXR in cell-based reporter gene assays (Raucy, 2003; Ma et al., 2004).

Environmental Chemicals

Several environmental contaminants have been reported to activate PXR signaling or increase the expression of PXR in various animal species. These environmental contaminants include pesticides, steroids, plasticizers, heavy metals, etc. Several insecticides including organochlorines and pyrethroids have been reported to activate hPXR and upregulate CYP3A4 mRNA expression (Milnes et al., 2008). The herbicide alachlor has been reported to activate PXR in vitro and upregulates CYP3A mRNA expression in rat liver (Mikamo et al., 2003; Lemaire et al., 2006). Using in vitro gene expression assays, 15 different classes of pesticides that act as hPXR activators have been identified as summarized in Table 1 (Lemaire et al., 2006). Activation of PXR and the corresponding increase in Cyp3a gene expression occur after exposure to nonylphenol in juvenile fish liver (Meucci and Arukwe, 2006). The pyrethroid insecticide cis-bifenthrin upregulates the mRNA and protein expression of PXR in the HepG2 cell line (Xiang et al., 2018). The heavy metal ions Ag+ and Pb2+ upregulate the PXR mRNA in embryonic zebrafish fibroblasts (Liu et al., 2019). In CYP3A4 transgenic (TG) mice, arsenic has been reported to increase the mRNA expression of both PXR and CYP3A4, as well as CYP3A4 protein expression (Medina-Diaz et al., 2009). Chronic uranium exposure has been reported to increase PXR mRNA expression in the brain, liver, and kidney of rats (Souidi et al., 2005). The noncoplanar polychlorinated biphenyls (PCBs) have been reported to activate hPXR (Jacobs et al., 2005; Al-Salman and Plant, 2012). Bisphenol A is an agonist of hPXR but not mPXR (Sui et al., 2012). Several formerly used flame retardants, such as the polybrominated diphenyl ethers (PBDEs) are activators of PXR of both human and mouse origins (Pacyniak et al., 2007; Sueyoshi et al., 2014). Phthalate esters are used in the manufacture of plastic products and are activators of both human and rodent PXR (Chang and Waxman, 2006).

Food Components

Several dietary components have been reported as activators of PXR of either humans or of other organisms. Mycotoxins are found in food of humans and animals and have been reported as activators of PXR (Ding et al., 2006; Ayed-Boussema et al., 2012a; Ayed-Boussema et al., 2012b). Aflatoxin B1, which is a potent liver carcinogen is a PXR activator and upregulates the expression of PXR-target genes (Ayed-Boussema et al., 2012a; Daujat-Chavanieu and Gerbal-Chaloin, 2020). Patulin, another mycotoxin associated with fruits, has been reported to activate PXR and its target genes in primary human hepatocytes (Ayed-Boussema et al., 2012b). Molecular docking showed isorhamnetin, a flavonol compound present in various fruits and vegetables, is a hPXR ligand and subsequently represses the NF-ĸB pathway (Dou et al., 2014). Menaquinone-4, a vitamin K2 analog and medication for osteoporosis, is a hPXR ligand and upregulates PXR-target gene expression in both in vivo and in vitro experiments (Tabb et al., 2003; Avior et al., 2015; Sultana et al., 2018). Vitamin E is a potent activator of hPXR with similar efficacy as rifampicin (Landes et al., 2003). A high fat diet (HFD) can lead to enhanced PXR signaling in mice (Saraswathi et al., 2017). The nutritional factor alpha-ketoglutarate can enhance PXR activity and downregulate the NF-ĸB signaling pathway, although the molecular mechanism needs to be further explored (He et al., 2017).

PXR Repressors

Although most studies in the literature have focused on PXR activators, PXR repressors have also been identified as summarized in Table 1. Phytoestrogens and phytochemicals including coumestrol and sulforaphane bind to the LBD of hPXR and inhibit the expression of PXR-target genes in both hepatocytes and in livers of humanized PXR-transgenic (hPXR-TG) mice (Wang et al., 2008). Sulforaphane, a phytochemical present in broccoli, binds to the LBD of hPXR and antagonizes the PXR signaling (Zhou et al., 2007). The antifungal drug ketoconazole is a well-known repressor of PXR activity in HepG2 liver cancer-derived cells, human hepatocytes, LS174T colon cancer-derived cells, as well as CV-1 cells cotransfected with plasmids expressing either pCMX-hPXR or pCMX-mPXR along with a CYP3A4 luciferase reporter plasmid (Huang et al., 2007). The antineoplastic chemical ET-743 suppresses hPXR signaling and downregulates MDR1 gene expression in vitro (Synold et al., 2001). The specific PXR antagonist # 70 is another compound that serves as a potent and selective repressor of hPXR (Lin et al., 2017). Lipopolysaccharides, which is produced by resident gram-negative bacteria, inhibits PXR expression and downregulates Cyp3a11 mRNA expression in mouse liver (Xu et al., 2004; Xu et al., 2005). Ochratoxin A, a potent mycotoxin produced by Aspergillus sp, is a repressor of PXR in the HepG2 cell line (Doricakova and Vrzal, 2015; Daujat-Chavanieu and Gerbal-Chaloin, 2020; Shen et al., 2020).

Regulation of Complex Gut-Liver Crosstalk

Previously, it was well-known that the major bile acid sensor farsenoid X receptor (FXR) is the primary receptor regulating the expression of host bile acid processing genes within the gut-liver axis. The intestinal activation of FXR by bile acids activate fibroblast growth factor 15 in mice and fibroblast growth factor 19 in humans, which provides a negative feedback regulation of the host hepatic bile acid biosynthesis through downregulating Cyp7a1, the rate-limiting bile acid synthetic enzyme in liver (Wang et al., 2012; Li and Chiang 2015; Xiang et al., 2021). In addition to FXR, emerging research showed that PXR also contributes to the regulation of gut-liver crosstalk. The nuclear receptor PXR is expressed in several tissues in the body including kidney, lung, placenta, and ovary, but PXR is predominantly expressed in the liver and small intestine (Mohandas, 2017; Kliewer et al, 2002; Burk et al, 2004). The intestinal-derived secondary bile acid, lithocholic acid (LCA) activates PXR in mouse liver and thus increases the expression of the PXR-target gene Cyp3a11 (Staudinger et al., 2001). In addition, PXR transcriptionally regulates several bile acid transporters within the gut-liver axis (Ntcp, Ostα, Ostβ, and Oatp1a4) (Beaudoin et al., 2020; Stauginder et al., 2001). However, organ-specific PXR-signaling has been observed. For example, the microbial tryptophan metabolite indole 3-propionic acid (IPA) is a PXR activator in intestine as evidenced upregulation of the PXR-target gene Mdr1 in mouse jejunum (Venkatesh et al., 2014); however, it does not readily activate PXR in mouse liver (Morgan et al., 2018). In contrast, other ligands such as St. John’s wort extract (with hyperforin being one of the active ingredients) increase the expression and activity of PXR-target genes in both the intestine and liver (Durr et al., 2000; Moore et al., 2000b; Cantoni et al., 2003). In summary, in addition to FXR, PXR also contributes to the regulation of genes involved in bile acid homeostasis and xenobiotic biotransformation within the gut-liver axis.

PXR, Novel Endogenous PXR Activators, and the Gut Microbiome

The interactions between host PXR and gut microbiome are bidirectional. First, distinct microbial metabolites act as PXR activators (Table 1) under pathophysiological conditions to modulate the expression of PXR-target genes in a tissue-specific manner. Second, PXR of the host impacts the gut microbiome composition and functions under physiologic, pharmacological, and toxicological conditions. This section will summarize the key findings regarding the bidirectional interactions between the host PXR signaling and the gut microbiome.

Regulation of the Host PXR Signaling by Microbial Metabolite

The most hydrophobic secondary BA generated from dehydroxylation reactions by the gut microbiota is LCA, which is the most toxic BA to hepatocytes at high concentrations, such as during cholestasis (Fickert et al., 2006; Woolbright et al., 2014; Xu et al., 2020). Toxic levels of LCA and other secondary BAs produce liver damage through inflammation, oxidative stress, DNA damage, and cell death, leading to both liver and colon cancers (Allen et al., 2011; Ajouz et al., 2014; Woolbright et al., 2014; Jia and Jeon, 2019). Dietary supplement with 0.5% LCA increased the mRNA of the prototypical PXR-target gene cytochrome P450 3a11 (Cyp3a11) in a PXR-dependent manner in livers of adult male mice; in addition, PXR serves as a sensor of LCA to protect against hepatotoxicity (Staudinger et al., 2001). LCA transactivates PXR of both human and mouse origins in luciferase reporter assays, and it increased Cyp3a11 mRNA in a PXR-dependent manner (8 mg per day for 4 days via oral gavage) (Xie et al., 2001). Gastrectomy increased the endogenous LCA, LCA-producing intestinal bacteria Bacteroides fragilis, PXR nuclear translocation, and Cyp3a11 mRNA expression in mouse liver (Ishii et al., 2014). Because the major BA sensor FXR is not activated by LCA, it is thought that LCA-mediated activation of PXR provides an important compensatory protective mechanism to reduce LCA overload and ameliorate liver injury (Jung et al., 2006; Ishii et al., 2014). In addition to LCA, deoxycholic acid (DCA), another microbially derived secondary BA, can also transactivate PXR (Xie et al., 2001).

The bacteria-derived tryptophan metabolite IPA is a PXR ligand in the mouse intestine (Venkatesh et al., 2014). Produced by the intestinal bacteria Clostridium sporogenes, IPA downregulates the proinflammatory cytokine tumor necrosis factor-α) in enterocytes and upregulates the mRNAs encoding tight junction proteins and protects the gut barrier integrity in a PXR-dependent manner (Venkatesh et al., 2014). Although IPA activates PXR in the mouse intestine, it does not activate PXR in the mouse liver (Morgan et al., 2018). However, circulating IPA activates PXR in the vascular endothelium of mice to reduce the vasodilatory responses to nitric oxide in isolated and cultured vessels in a PXR-dependent manner. This suggests that IPA-mediated PXR activity plays a key role in endothelial function (Pulakazhi Venu et al., 2019). This also indicates that PXR activation by IPA is tissue specific.

Based on the conclusion above that IPA activates PXR, it was proposed that microbial indole metabolite mimicry might be a novel strategy for drug discovery. In fact, the functionalized indole derivatives have generated first-in-class noncytotoxic PXR agonists. The lead compounds are Felix Kopp Kortagere (FKK) 5 and FKK6 that activate PXR to reduce inflammation. FKK6, later called CVK003, is a direct PXR-binding ligand and induces PXR-target gene expression in cells, human organoids, and mice. Through PXR activation, FKK6 represses proinflammatory cytokines in humanized PXR transgenic mice (Dvořák et al., 2020a). The removal of the phenyl-sulfonyl group of FKK6 shifts the agonist activity away from PXR toward the aryl hydrocarbon receptor, whereas the addition of the imidazole pyridyl group preserves PXR activity in vitro (Li et al., 2021). Targeting the microbial indole metabolite mimicry serves as an important mechanism to understand the crosstalk between PXR and other important xenobiotic-sensing transcription factors such as the aryl hydrocarbon receptor (Dvořák et al., 2020b; Li et al., 2021).

Necessity of the Gut Microbiome in the Host PXR Signaling under Basal and Toxicological Conditions

The role of the gut microbiome in modulating the basal PXR signaling was first noted by quantifying the expression and enzyme activities of the prototypical PXR-target gene Cyp3a in livers of germ free (GF) mice (Toda et al., 2009b) and in livers of antibiotic-treated conventional (CV) mice (Toda et al., 2009a). Ciprofloxacin, which is a quinolone antibiotic, decreases Cyp3a11 expression and triazolam metabolism in mouse liver by reducing LCA-producing intestinal bacteria, whereas LCA treatment increased Cyp3a11 expression in GF mice (Toda et al., 2009a). Another study showed that most of the major Cyps and the PXR gene expression were lower in the livers of GF mice (Toda et al., 2009b), suggesting that intestinal bacteria maintain constitutive PXR-signaling in mouse liver. Transcriptomic-wide investigations including microarray (Bjorkholm et al., 2009) and RNA-Seq sequencing (Selwyn et al., 2015b) in livers of CV and GF mice further demonstrated that gut microbiome is necessary for maintaining the basal expression of various xenobiotic-processing genes and PXR-signaling. In fact, xenobiotic metabolism ranked among the topmost differentially regulated networks in the entire liver transcriptome of adult male GF mice (Selwyn et al., 2015a). The GF-mediated downregulation of Cyp3a11 gene expression is modified by age and blunted the ontogenic increase of Cyp3a11 in mouse liver (Selwyn et al., 2015a). Interestingly, conventionalization through exposing the GF mice with feces from CV mice restored the constitutive expression of Cyp3a11 mRNA and protein in the liver (Selwyn et al., 2016), and this observation further confirmed the necessity of gut microbiome in the basal expression of this PXR-target gene in the liver. Extended investigations in various sections of the intestine of CV and GF mice showed that the gut microbiome is also important in maintaining the constitutive expression of Cyp3a in an intestinal section-specific manner (Fu et al., 2017). Therefore, the gut microbiome is a functional modifier of PXR and Cyp3a-mediated drug metabolism in the liver and intestine under basal conditions (Dempsey and Cui, 2019).

After exposure to known PXR-activating chemicals, the gut microbiome may serve as a novel modifier of PXR-target gene expression in the liver. The previously used flame retardants PBDEs are bioaccumulative and thus persistent in the environment long after their use was banned. Among the 209 possible PBDE congeners, the noncoplanar BDE-47 and BDE-99 are known to activate PXR in mouse liver (Pacyniak et al., 2007). Interestingly, oral exposure to BDE-47 and BDE-99 upregulated the mRNA of many drug-processing genes, including the PXR-target gene Cyp3a11 in mouse liver. This upregulation was further augmented by the lack of gut microbiome (Li et al., 2017), suggesting that the gut microbiome inactivates the PBDE parent compounds or metabolites, thus less PXR activators are available under CV conditions. In serum of CV mice, oral exposure to BDE-47 and BDE-99 decreased the tryptophan microbial metabolite IPA (Scoville et al., 2019), which is a known endogenous PXR ligand in mouse intestine (Venkatesh et al., 2014). The imbalance between endogenous versus exogenous PXR activators after xenobiotic exposure may serve as a contributing mechanism for drug-drug and food-drug interactions.

Regulation of Gut Microbiome by PXR-Activating Xenobiotics

Although the intestinal microbiome modulates the basal and inducible PXR signaling as discussed above, the host PXR gene and exposure to PXR activators can reciprocally modulate the gut microbiome composition and metabolism. After oral exposure to PCN, which is the prototypical PXR ligand in mice, there was a distinct change in the gut microbiome as evidenced by the principal coordinate analysis of beta diversity (Dempsey et al., 2019). At the class level, PCN decreased Actinobacteria and a taxon in the Firmicutes phylum but increased Gammaproteobacteria. At the genus level, PCN decreased Dorea, Anaeroplasma, and a taxon in the Peptococcaceae family, but increased Ruminococcus. In addition, PCN decreased two taxa in Bifidobacterium, which is known to have BA deconjugation activities (Foley et al., 2019), which corresponds to decreased gene abundance of the bile salt hydrolase in the microbial DNA from PCN-exposed mice and reduced expression (Dempsey et al., 2019). PCN also tended to decrease the microbial DNA encoding the bile acid-inducible operon CD and baiJ, although a statistical significance was not achieved. In livers of PCN-exposed CV mice, there was a decrease in the total secondary BAs, and this was due to a significant reduction in DCA, 3-dehydrocholic acid, 12-dehydrocholic acid, and a trend of a decrease (not significant) in tauro-lithocholic acid and tauro-hyodeoxycholic acid (Dempsey et al., 2019). In summary, pharmacological activation of PXR by its prototypical ligand PCN downregulates distinct BA-metabolizing intestinal bacteria and alters BA homeostasis.

After exposure to PXR-activating therapeutic drugs, the gut microbiome can also be modulated. The cholesterol-lowering statins are known PXR activators (Howe et al., 2011; Hoffart et al., 2012). Two PXR-activating statins, namely atorvastatin and pravastatin, produce gut dysbiosis and reduced butyrate production in a PXR-dependent manner in mice (Caparros-Martin et al., 2017).

After exposure to PXR-activating environmental chemicals, gut dysbiosis has been observed (Cheng et al., 2018; Li et al., 2018; Scoville et al., 2019; Cruz et al., 2020; Lim et al., 2020; Gomez et al., 2021), although caution is needed in interpreting the results, as these environmental toxicants may also have off-target effects on the gut microbiome independent from PXR activation. Oral exposure to BDE-47 and BDE-99, which are known to activate PXR and CAR in mouse liver (Pacyniak et al., 2007), produced profound gut dysbiosis as evidenced by decreased alpha diversity and 45 differentially regulated bacteria in the large intestinal content of adult male mice (Li et al., 2018). Most notably, there was an increase in Akkermansia muciniphila and Erysipelotrichaceae Allobaculum spp., which have been reported to have anti-inflammatory and antiobesity functions (Png et al., 2010; Ravussin et al., 2012; Derrien et al., 2017). BDE-99 increased many unconjugated BAs in multiple biocompartments in a gut microbiome-dependent manner, which correlates with an increase in microbial 7α-dehydroxylation enzymes for secondary BA synthesis and increased expression of host intestinal transporters for BA absorption. PBDEs also downregulated host BA-synthetic enzymes and transporters in mouse livers in a gut microbiome-dependent manner (Li et al., 2018). In addition to BAs, BDE-47 and BDE-99 also modulated other intermediary metabolites such as those from amino acid and carbohydrate metabolism (Scoville et al., 2019). Among serum, liver, as well as small and large intestinal content, the large intestinal content is the biocompartment where PBDEs altered the largest number of aqueous metabolites, and most of the differential regulation was observed in the GF mice. For example, the gut microbiome was necessary for PBDE-mediated downregulation in branched-chain and aromatic amino acid metabolites, whereas gene-metabolite networks revealed a positive association between the mRNA expression of the hepatic glycan synthesis gene α-1,6-mannosyltransferase and mannose, which are important for protein glycosylation (Scoville et al., 2019). Thus, the lack of gut microbiota augmented the PBDE-mediated effects on intermediary metabolism in adult male mice. Maternal exposure to BDE-47 produced persistent gut dysbiosis in adult male mouse pups and persistently increased fecal and hepatic BAs within the 12α hydroxylation pathway, which corresponds to the upregulation of the hepatic rate-limiting BA-synthetic enzyme Cyp7a1 (Gomez et al., 2021). For all the studies described above, follow-up investigations using PXR-null mice are necessary to determine whether the observed effects by PBDEs are PXR-dependent. The PBDE-mediated dysbiosis in human microbiome was further investigated in a fermentation system using fresh human stool, and it was shown that PBDEs produced an imbalance in sulfur, short-chain fatty acids, and aromatic organic compounds and altered the microbial volatolome in a dose- and time-dependent manner (Cruz et al., 2020).

Several noncoplaner congeners of the Fox River PCBs mixture are known PXR activators, and oral exposure to the Fox River mixture (6 mg/kg) produced gut dysbiosis including an upregulation in A. muciniphila, Clostridium scindens, and Enterococcus in large intestinal pellet of adult female CV mice. There was also an increase in multiple BAs in serum and small intestinal pellets in a gut microbiota-dependent manner, and Pearson’s correlation analysis identified a positive correlation between 5 taxa and most secondary BAs (Cheng et al., 2018). At the dose of 30 mg/kg of PCBs, NADP and arginine are predicted to interact with the drug-metabolizing enzymes within the Cyp1-3 family, and this was also highly correlated with the presence of Ruminiclostridium and Roseburia. This suggests a novel role of the gut-liver axis in PCB-mediated effect on intermediary metabolism (Lim et al., 2020). In addition to the Fox River PCB mixture, the Aroclor1260 PCB mixture also altered the composition of the gut microbiome in a diet-induced obese mouse model and altered beta diversity in a PXR-dependent manner (Wahlang et al., 2021).

Regulation of Gut Microbiome by the Host PXR Gene under Basal and Pathophysiological Conditions

Although PXR has been extensively studied and well-recognized as a xenobiotic-sensing receptor for drugs, environmental chemicals, and nutraceuticals, very recent studies showed that this classic drug receptor also plays important biologic functions under basal conditions (Little et al., 2021) and pathophysiological conditions, such as diet-induced nonalcoholic steatohepatitis and toxicant-induced nonalcoholic steatohepatitis (Spruiell et al., 2014a; Spruiell et al., 2014b; Wahlang et al., 2021). Pharmacological activation of PXR also has anti-inflammatory functions (Cheng et al., 2012). Interestingly, such novel PXR-mediated functions are associated with PXR-dependent modulation of the gut microbiome and microbial metabolites.

Under physiologic conditions, studies using PXR-null mice have shown that the absence of PXR increased the microbial richness and the proinflammatory bacteria (Helicobacteraceae and Helicobacter) and decreased the fecal levels of many abundant taurine-conjugated BAs. Thus, PXR may function to maintain gut flora and immune surveillance under basal conditions (Little et al., 2021). The suppression of microbial abundance by PXR under basal conditions was also independently observed in another study (Wahlang et al., 2021). Interestingly, the basal effect of PXR on the gut microbiome was distinct from pharmacological and toxicological activation of PXR (Cheng et al., 2018; Li et al., 2018; Dempsey et al., 2019; Lim et al., 2020; Little et al., 2021). Bona fide PXR-targeted intestinal bacteria Dorea, Mogibacteriaceae, Ruminococcaceae, Streptococcus, and Anaeroplasma were consistently suppressed by PXR under both basal and PXR-activated conditions (Cheng et al., 2018; Li et al., 2018; Dempsey and Cui, 2019; Lim et al., 2020; Little et al., 2021). Interestingly, hPXR-TG mice had a distinct microbial profile and a general trend of reduced fecal DCA compared with wild type mice, suggesting that the species difference in the PXR protein may lead to different gut microbiome configurations and functions (Little et al., 2021).

The PXR gene can produce adverse effects in pathophysiological conditions. In a HFD-induced obese mouse model, it was demonstrated that the presence of PXR worsens obesity as evidenced by protection from weight gain and liver steatosis in PXR-null mice (Spruiell et al., 2014a; Spruiell et al., 2014b). PXR activation is also detrimental in the regulation of glucose metabolism (Hukkanen et al., 2014). Specifically, in mice, PXR-deficiency improves HFD-induced obesity and genetically induced obesity (i.e., the ob/ob mice), which are models for type 2 diabetes (He et al., 2013; Zhao et al., 2017). Interestingly, hPXR-TG mice also carry a genetic predisposition for type 2 diabetes (Spruiell et al., 2014a). Pregnane X receptor-transgenic mice have impaired glucose utilization, elevated fasting glucose levels, and severely impaired glucose tolerance during high fat diet treatment, suggesting there is a species difference of PXR in regulating obesity and glucose signaling (Spruiell et al., 2014a; Spruiell et al., 2014b). Interestingly, the HFD-mediated increase in intestinal Firmicutes/Bacteroidetes ratio, which is a hallmark for obesity and increased energy harvest from diet (Turnbaugh et al., 2006), was completely abolished in male PXR-null mice. There was also a PXR-dependent, HFD-mediated decrease in the antiobese Allobaculum and the anti-inflammatory Bifidobacterium (Kim et al., 2021). The PXR-dependent gut dysbiosis after an HFD-induced obesity was associated with PXR-enhanced weight gain, hepatic steatosis, inflammation, as well as PXR-dependent upregulation in hepatic genes involved in microbial response, inflammation, oxidative stress, and cancer (Kim et al., 2021). In contrast to the higher susceptibility to HFD-induced nonalcoholic fatty liver disease phenotype in male mice, the resistance to non-alcoholic fatty liver disease in females may be explained by a PXR-dependent decrease in proinflammatory bacteria (Ruminococcus gnavus and Peptococcaceae) (Kim et al., 2021). In a toxicant-induced nonalcoholic steatohepatitis mouse model exposed to both HFD and the Aroclor1260 PCB mixture, PXR-dependent gut dysbiosis was also noted including increased Actinobacteria and Verrucomicrobia abundance in PXR-null mice (Wahlang et al., 2021). In conclusion, PXR exacerbates hepatic steatosis and inflammation accompanied by obesity- and inflammation-prone gut microbiome signature, suggesting that gut microbiome may contribute to PXR-mediated exacerbation of obesity.

Modifying Factors of PXR-Signaling

Species Difference

Overview

It’s well-known that there are species differences in PXR activity (Jones et al., 2000; LeCluyse, 2001; Xie and Evans, 2001). Activation and repression of PXR among various species contribute to species-specific efficacy and toxicity of pharmaceuticals and other xenobiotics in humans, animals, and the ecosystem (Pinne et al., 2016; Creusot et al., 2021). As discussed earlier, rifampicin, an antituberculosis drug, and SR12813 selectively activates PXR in humans and rabbits, whereas PCN is a classic synthetic compound that activates PXR in rodents (Li and Chiang, 2005; Marek et al., 2005; Li and Chiang, 2006; Ma et al., 2008). Using PXR and its prototypical target gene CYP3A/Cyp3a expression as a read-out, previous investigations revealed similarities and differences in activation of PXR and toxicities from using endogenous and exogenous compounds in hPXR, mPXR, rat PXR (rPXR), and zebrafish PXR (zfPXR) (Reschly and Krasowski, 2006; Reschly et al., 2007; Krasowski et al., 2011). For example, tropanyl 3,5-dimethylbenzoate, a 5-HT3 receptor agonist, activates hPXR but not rPXR (Shukla et al., 2011). The gut microbiota is capable of producing vitamin K2 (Conly and Stein, 1992). Interestingly, vitamin K2 acts as a PXR activator in humans but not in zebrafish (Creusot et al., 2021).

Although many chemicals activate PXR in a species-specific manner, common PXR-activating compounds across multiple species have also been identified. Using human cell lines including LS174T, LoVo, HCT116, and a mouse xenograft model, activation of PXR has been observed in both humans and mice using rifampicin and PCN, respectively, along with enhanced colon cancer cell growth, proliferation, invasion, and metastasis through activation of fibroblast growth factor 19 signaling (Wang et al., 2011). The microbial-derived secondary BAs LCA and DCA, as well as the primary BA chenodeoxycholic acid (CDCA) activates PXR in humans and rodents (Xie et al., 2001). Benzo[a]pyrene, a polyaromatic hydrocarbon, activates hPXR and mPXR, but not zfPXR (Cui et al., 2017; Creusot et al., 2021). Pharmaceutics, such as hyperforin, mevastatin, and n-butyl-4-aminobenzoate, activates hPXR but not zfPXR (Creusot et al., 2021). Other chemicals within classes of pharmaceutics, phytochemicals, environmental chemicals, endogenous compounds, and pesticides, and their examples of PXR activation are listed in Table 1.

Evolutionary Differences of PXR Across Species

The vitamin D receptor and PXR are suggested to have been separated from a duplication process of a common ancestral gene (Reschly and Krasowski, 2006). Due to speciation and evolutionary pressure, a distinction of functional differences in PXR and its LBD have likely arisen (Reschly and Krasowski, 2006; Reschly et al., 2007; Krasowski et al., 2011). It was shown that hPXR, mRXR, rPXR, and rbPXR share approximately 95% identity in their DNA binding domain ut share only 75%–80% in their amino acid sequences in the LBD (LeCluyse, 2001). This indicates that species-specific PXR activation is likely a result of adaptation to different environmental exposures (LeCluyse, 2001; Ekins et al., 2008), and it is supported by structural analysis of the PXR LBD (Watkins et al., 2001; Ngan et al., 2009). The amino acid substitution may result in changes in the LBD. In the PXR LBD, five out of nine amino acids in mPXR are conserved in hPXR, and the remaining four residues, Phe184, Arg203, Lys334, and Ser414, are substituted by Ser187, Leu203, Glu334, and Ile414, respectively (LeCluyse, 2001). Conservation of the five amino acids between mPXR and hPXR supports activation of PXR by certain chemicals, such as LCA in humans and mice. Therefore, substitutions in amino acid residues are likely responsible for the differential response of PXR in various species.

Sex Difference in PXR Activity

The expression and activity of PXR and its targets differ between males and females. In mouse models, the expression of Cyp3a11 and Cyp3a25, the prototypical targets of PXR in mice, is higher in females than males (Cui et al., 2012; Lu et al., 2013). Likewise, expression levels of PXR targets are slightly different between male and females in humans (Wolbold et al., 2003; Scandlyn et al., 2008). Because PXR is a critical component in xenobiotic biotransformation, characterizing and investigating the sex difference of PXR from xenobiotic exposures and diseases remain an important task. Correspondingly, drugs that are substrates of CYP3A4, such as cyclosporine, erythromycin, nifedipine, and ifosfamide have higher clearance rates in women (Austin et al., 1980; Kahan et al., 1986; Krecic-Shepard et al., 2000; Schmidt et al., 2001), which may lead to gender-dependent dosage regimens and toxicological effects because of species difference in the PXR-CYP3A4 pathway (Tanaka, 1999; Parkinson et al., 2004; Scandlyn et al., 2008).

Regarding the sex difference in toxicological responses related to PXR signaling, the hepatic Cyp3a11 gene expression from exposure to PCBs is higher in female mice than in male mice (Wahlang et al., 2019). Exposure to LCA to PXR-null mice produced cholestasis more prominently in males than in females (Uppal et al., 2005). When wild type (WT) and Cyp3a null mice were fed 60% high fat diet, female Cyp3a knockout (KO) mice gained 50% less weight than WT mice, but male Cyp3a KO mice gained more weight than the WT control. Interestingly, HFD increased the expression of PXR in Cyp3a KO female mice; whereas PXR was downregulated in male Cyp3a KO mice (Kumar et al., 2018). In humans, the risk of drug-induced hepatotoxicity during antituberculosis treatment from rifampicin is higher in women than in men (Shehu et al., 2016). Wang et al. hypothesized that sex-specific single nucleotide polymorphisms genotype and the resulting haplotype of PXR differentially regulate the expression of CYP3A4, leading to the sex-specific influence of hepatotoxicity (Wang et al., 2015). Significant associations were found between two PXR haplotypes, h001101 and h000110, and increased hepatotoxicity during antituberculosis treatment with rifampicin, isoniazid, or pyrazinamide (Wang et al., 2015). Single nucleotide polymorphism and haplotype differences of PXR may be a significant reason for differences in PXR activity.

The gut microbiome is suggested to be a critical driver of gender differences of PXR. GF mice had attenuated sex differences in PXR and its target genes in the liver, compared with CV mice (Weger et al., 2019). In addition, PXR also reciprocally drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice, in that the expression of most microbiota-sensitive hepatic genes in response to antibiotic-mediated depletion of microbiota in mice were PXR-dependent in males, but not in females (Barretto et al., 2021). Pathway enrichment analysis suggests that that microbiota-PXR interaction regulates fatty acid and xenobiotic metabolism, and data on liver triglyceride content indicate that antibiotic treatment reduced liver triglyceride content and hampered xenobiotic metabolism in male mice in a PXR-dependent manner (Barretto et al., 2021).

PXR and Critical Time Windows

Using the prototypical PXR-target gene Cyp3a11 as a read-out for PXR activation, it was shown that Cyp3a11 mRNA undergoes extensive regulation at critical time windows. For example, during mouse liver development, Cyp3a11 mRNA is low before birth, peaks around postnatal day 5, and maintains at high levels until young adulthood (Hart et al., 2009). It should be noted that the ontogenic regulation of Cyp3a11 may not be solely PXR dependent, as it has been shown that district chromatin epigenetic signatures, such as increased permissive mark histone H3 lysine 4 di-methylation positively associates with the ontogenic increase of Cyp3a11 mRNA in developing mouse liver (Li et al., 2009). During human liver development, the Cyp3a11 ortholog CYP3A4 gene locus is also extensively modified by the histone code, and the postnatal liver has reduced occupancy of repressive histone marks and higher occupancy of active histone marks compared with the fetal liver (Giebel et al., 2016). During aging, Cyp3a11 mRNA displays a consistent male-predominant pattern and decreases earlier in the livers of female mice than age-matched male mice (Fu et al., 2012). Cyp3a11 mRNA also exhibits diurnal variations between day and night, with higher expression around 4 AM followed by a decrease to relatively steady levels during the daytime (Zhang et al., 2009). Activation of PXR using its prototypical ligand PCN at various developmental ages showed that the highest fold-induction occurred in the 60-day-old young adult, followed by postnatal day 5 (Li et al., 2016b). Neonatal activation of PXR also persistently downregulated the mRNA and protein expression of multiple CYP4A isoforms, which are prototypical target genes of the lipid-sensing nuclear receptor peroxisome proliferator-activated receptor-α, in livers of adult male mouse pups in a PXR-dependent manner (Li et al., 2016a).

Pharmacological and Mathematical Models of PXR

There have been a few mathematical models developed to describe PXR activation and CYP3A upregulation in humans and rodents. These mathematical models implemented a system of ordinary differential equations to organize and simulate the molecular activation of PXR, signaling pathway, and induction of its targets. One of the first to depict a compartmental model of CYP3A4 gene regulation by PXR considered the standard cyclical process of PXR activation: rifampicin enters the cell and binds to PXR, which forms a heterodimer with RXRα; the PXR/RXRα binds to DNA and induces CYP3A4 mRNA, which is translated into protein; CYP3A4 mRNA is degraded and translated protein metabolizes the rifampicin in the cell (Luke et al., 2010). This model included a feedback loop and used zero- and first-order kinetics to model the steady-state mRNA levels of CYP3A4 and incorporated plasma and liver in their compartmental model (Luke et al., 2010).

Similar to the model by Luke et al., the rPXR pharmacokinetic/pharmacodynamic (PK/PD) model developed by Li et al. describes the change in levels of CYP3A1 and CYP3A2 with respect to time after the activation of rPXR from dexamethasone exposure at various drug concentrations (Li et al., 2012). The model formulated by Li et al. comprised of in vivo exposure to dexamethasone by intraperitoneal injection (100 mg/kg), measurement of total 6β-testosterone hydroxylation formation enzyme activity, and CYP3A1 and CYP3A2 mRNAs and protein levels, and contained two compartments, i.e., blood and liver (Li et al., 2012). The resulting model, upon estimation and calculation of parameters, such as clearance, apparent volume of distribution, and duration of zero-order absorption, and using transit compartments, was able to show the concentration-induction response relationship between dexamethasone and the prototypical rPXR targets (Li et al., 2012).

Data for the conceptual models for PXR can be obtained relatively easily by RT-qPCR (reverse trancription-quantitative polymmerase chain reaction) and western blots (Luke et al., 2010; Bailey et al., 2011; Kolodkin et al., 2013). Additional parameters, such as cytoplasm-to-nucleus mRNA translocation and RNA processing, can be performed to further improve physiologic and molecular relevance. These improved models can serve as important first-pass detection of CYP3A induction and PXR activation in novel compounds and can be used as a start of investigating a systems approach of PXR and other receptors and their targets, i.e., PXR and the glucocorticoid receptor (Kolodkin et al., 2013). However, no mathematical or statistical model describing the PXR-CYP3A relationship across species has been developed. Therefore, the development and expansion of such models will allow future research to investigate CYP3A and PXR mRNA or protein induction from cellular experiments in newly studied organisms have a good potential in assessing toxicity and drug-drug interactions across species.

Current Challenges and Knowledge Gaps

With the expansion of research on PXR recently, several challenges and knowledge gaps are noted in this area. First, prototypical PXR-target genes (e.g., Cyp3a) may be regulated by other mechanisms such as epigenetic modifiers and other transcription factors, thus they may not be a bona fide biomarker for PXR activation. Second, species differences in both PXR and the PXR-modulating endogenous molecules between humans and animal models continue to be a challenge in translational research. In addition, although several novel endogenous PXR ligands are being resolved, there is a knowledge gap regarding how other endogenous small molecules among the vast majority of poorly characterized “dark matter” within the metabolome modulate PXR. Certain endogenous molecules may serve as potent PXR ligands in animal models but only weak PXR ligands or display no activity toward PXR in humans; in addition, these molecules may serve as potent PXR ligands in certain tissues (e.g., intestine) but only have weak PXR-modulating activities in other tissues (liver). Last but not least, the consequence of PXR activation may be context specific and can be either beneficial (e.g., chemical detoxification and anti-inflammation) or harmful (e.g., drug-drug interactions and promoting nonalcoholic steatohepatitis). Therefore, it is very important to understand the complexity of the species difference, tissue specificity, and context-specificity duality of PXR modulation, and additional research efforts are needed to further characterize PXR target genes in different organs and species as well as novel PXR-modulating molecules.

Within the challenges discussed above, we may find new opportunities to address them: strategies in derivatizing endogenous PXR ligands to improve their activities toward human PXR and tissues other than their original functional sites may provide novel therapeutic options to treat complex human disease while bypassing the adverse drug reactions. In addition, with the availability of single cell transcriptomics and single cell metabolomics, it is possible to improve the precision and resolution of understanding the PXR functions and modulating factors.

Overall Conclusion and Closing Remarks

Taken together, as summarized in Fig. 1, PXR is a versatile xenobiotic-sensing nuclear receptor that has been rediscovered as a critical modulator for intermediary metabolism and metabolic diseases. Notably, PXR plays critical roles within the gut-liver axis within the context of exposures and disease outcomes. PXR activity can be modulated under basal, physiologic, pathophysiological, pharmacological, and toxicological conditions by a variety of environmental factors. These factors include drugs, environmental chemicals, dietary constituents, microbial metabolites, etc. Modifying factors such as sex, age, exposure time windows, and species specificity may interact the PXR signaling within the gut liver axis. Although the well-known outcomes of PXR activation with are drug-drug interactions through transcriptional regulation of various host genes involved in xenobiotic biotransformation, studies in the literature have also discovered bona fide PXR-targeted intestinal bacteria that are suppressed by PXR, as well as the importance of PXR in modulating inflammation and intermediary metabolism. Additional research using targeted and untargeted metabolomics is needed to further expand our knowledge regarding novel PXR-modulating small molecules from the diet, microbiome, and other exposures. It is also important to discover individual microbes and complex microbial symbiotic/competitive interactions that are involved in the production or consumption of PXR-modulating molecules. The discovery of novel endogenous PXR modulators is expected to aid in developing novel therapeutic modalities for drug-drug interactions, food-drug interactions, drug-toxicant interactions, as well as PXR-mediated metabolic diseases. We think it is also important to study the modulating of PXR-signaling by context-specific chemical mixtures, involving coexposures of both exogenous and endogenous PXR-modulating molecules. Due to the known species difference of PXR, it is important to continue utilizing humanized PXR transgenic models and in vitro systems to crossreference findings in various animal species. Development and expansion of mathematical models will allow future research to investigate PXR-CYP3A induction to investigate species and gender differences. Characterizing the sex difference in PXR-signaling continues to be a research priority, and incorporating additional metagenomics and metabolomics approaches will facilitate the identification of novel regulators that drive the gender-divergent PXR modulation and response. It is also important to further investigate the interactions between PXR and other transcription factors as well as cofactors. Additionally, relatively less is known about PXR and the gut-liver axis among the pediatric population. Further understanding the role of PXR in pediatric pharmaco-metagenomics is important to improve the safety and efficacy of using drugs in this vulnerable population.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Overall summary of PXR and the gut-liver axis within the context of exposures and outcomes. Briefly, PXR activity can be modulated under basal, physiologic, pathophysiological, pharmacological, and toxicological conditions by a variety of environmental factors. These factors include drugs, environmental chemicals, dietary constituents, microbial metabolites, etc. Modifying factors such as sex, age, exposure time windows, and species specificity may interact the PXR signaling within the gut liver axis. Although the well-known outcomes of PXR activation with are drug-drug interactions through transcriptional regulation of various host genes involved in xenobiotic biotransformation, studies in the literature have also discovered bona fide PXR-targeted intestinal bacteria that are suppressed by PXR as well as the importance of PXR in modulating inflammation and intermediary metabolism.

View this table:
  • View inline
  • View popup
TABLE 1

PXR-modulating chemicals

Acknowledgments

The authors would like to thank Dr. Curtis D. Klaassen for editing the manuscript.

Authorship Contributions

Participated in research design: Dutta, Lim, Cui. Performed data analysis: Dutta, Lim, Cui. Wrote or contributed to the writing of the manuscript: Dutta, Lim, Cui.

Footnotes

    • Received February 10, 2021.
    • Accepted December 2, 2021.
  • This work was supported by National Institutes of Health National Institute of Environmental Health Sciences [Grants R01-ES025708, R01-ES030197, and R01-ES031098]; National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM111381]; the University of Washington Center for Exposures, Diseases, Genomics, and Environment [Grant P30ES007033]; Environmental Pathology/Toxicology Training Program [Grant T32ES007032]; the University of Washington Sheldon Murphy Endowment; and the University of Washington Environmental Health and Microbiome Research Center.

  • No author has an actual or perceived conflict of interest with the contents of this article.

  • ↵1 M.D. and J.J.L. contributed equally to this work.

  • https://dx.doi.org/10.1124/dmd.121.000415.

ABBREVIATIONS

BA
bile acid
CV
conventional
CYP
cytochrome P450
DCA
deoxycholic acid
FKK
Felix Kopp Kortagere
FXR
farnesoid X receptor
GF
germ free
HFD
high fat diet
hPXR
human pregnane X receptor
hPXR-TG
human pregnane X receptor-transgenic
IPA
indole-3-propionic acid
KO
knock out
LBD
ligand binding domain
LCA
lithocholic acid
MDR1
multidrug resistance 1
mPXR
mouse pregnane X receptor
Oatp
organic anion transporting polypeptide
PBDE
polybrominated diphenyl ethers
PCB
polychlorinated biphenyl
PCN
pregnenolone-16α-carbonitrile
PXR
pregnane X receptor
rPXR
rat PXR
RXR
retinoic X receptor
TG
transgenic
WT
wild type
zfPXR
zebrafish PXR
  • Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics

References

    1. Abass K,
    2. Lämsä V,
    3. Reponen P,
    4. Küblbeck J,
    5. Honkakoski P,
    6. Mattila S,
    7. Pelkonen O, and
    8. Hakkola J.
    Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17–26.
    OpenUrlCrossRefPubMed
  1. ↵
    1. Ajouz H,
    2. Mukherji D, and
    3. Shamseddine A
    (2014) Secondary bile acids: an underrecognized cause of colon cancer. World J Surg Oncol 12:164.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Aleksunes LM and
    2. Klaassen CD
    (2012) Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice. Drug Metab Dispos 40:1366–1379.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Allen K,
    2. Jaeschke H, and
    3. Copple BL
    (2011) Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 178:175–186.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Alnouti Y and
    2. Klaassen CD
    (2008) Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. J Pharmacol Exp Ther 324:612–621.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Al-Salman F and
    2. Plant N
    (2012) Non-coplanar polychlorinated biphenyls (PCBs) are direct agonists for the human pregnane-X receptor and constitutive androstane receptor, and activate target gene expression in a tissue-specific manner. Toxicol Appl Pharmacol 263:7–13.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Austin KL,
    2. Mather LE,
    3. Philpot CR, and
    4. McDonald PJ
    (1980) Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 10:273–279.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Avior Y,
    2. Levy G,
    3. Zimerman M,
    4. Kitsberg D,
    5. Schwartz R,
    6. Sadeh R,
    7. Moussaieff A,
    8. Cohen M,
    9. Itskovitz-Eldor J, and
    10. Nahmias Y
    (2015) Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes. Hepatology 62:265–278.
    OpenUrl
  8. ↵
    1. Ayed-Boussema I,
    2. Pascussi JM,
    3. Maurel P,
    4. Bacha H, and
    5. Hassen W
    (2012a) Effect of aflatoxin B1 on nuclear receptors PXR, CAR, and AhR and their target cytochromes P450 mRNA expression in primary cultures of human hepatocytes. Int J Toxicol 31:86–93.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ayed-Boussema I,
    2. Pascussi JM,
    3. Rjiba K,
    4. Maurel P,
    5. Bacha H, and
    6. Hassen W
    (2012b) The mycotoxin, patulin, increases the expression of PXR and AhR and their target cytochrome P450s in primary cultured human hepatocytes. Drug Chem Toxicol 35:241–250.
    OpenUrlPubMed
  10. ↵
    1. Bailey I,
    2. Gibson GG,
    3. Plant K,
    4. Graham M, and
    5. Plant N
    (2011) A PXR-mediated negative feedback loop attenuates the expression of CYP3A in response to the PXR agonist pregnenalone-16α-carbonitrile. PLoS One 6:e16703.
    OpenUrlPubMed
    1. Banerjee M,
    2. Robbins D, and
    3. Chen T.
    Targeting xenobiotic receptors P XR and CAR in human diseases. Drug Discov Today. 2015, May;20(5):618–28.
    OpenUrlCrossRefPubMed
    1. Barrett JR.
    BPA and P XR activation: human receptor is affected, mouse receptor is not. Environ Health Perspect. 2012, Mar;120(3):A122.
    OpenUrlPubMed
  11. ↵
    1. Barretto SA,
    2. Lasserre F,
    3. Huillet M,
    4. Régnier M,
    5. Polizzi A,
    6. Lippi Y,
    7. Fougerat A,
    8. Person E,
    9. Bruel S,
    10. Bétoulières C, et al.
    (2021) The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice. Microbiome 9:93 10.1186/s40168-021-01050-9.
    OpenUrl
  12. ↵
    1. Beaudoin JJ,
    2. Brouwer KLR, and
    3. Malinen MM
    (2020) Novel insights into the organic solute transporter alpha/beta, OSTα/β: from the bench to the bedside. Pharmacol Ther 211:107542.
    OpenUrl
  13. ↵
    1. Bertilsson G,
    2. Heidrich J,
    3. Svensson K,
    4. Asman M,
    5. Jendeberg L,
    6. Sydow-Bäckman M,
    7. Ohlsson R,
    8. Postlind H,
    9. Blomquist P, and
    10. Berkenstam A
    (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208–12213.
    OpenUrlAbstract/FREE Full Text
    1. Bjork JA,
    2. Butenhoff JL, and
    3. Wallace KB.
    Multiplicity of nuclear receptor activation by P FOA and P FOS in primary human and rodent hepatocytes. Toxicology. 2011 Oct 9;288(1-3):8–17.
    OpenUrlCrossRefPubMed
    1. Björkholm B,
    2. Bok CM,
    3. Lundin A,
    4. Rafter J,
    5. Hibberd ML, and
    6. Pettersson S
    (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One 4:e6958.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Blumberg B,
    2. Sabbagh W Jr.,
    3. Juguilon H,
    4. Bolado J Jr.,
    5. van Meter CM,
    6. Ong ES, and
    7. Evans RM
    (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195–3205.
    OpenUrlAbstract/FREE Full Text
    1. Brewer CT and
    2. Chen T.
    P XR variants: the impact on drug metabolism and therapeutic responses. Acta Pharm Sin B. 2016 Sep;6(5):441–449.
    OpenUrl
  15. ↵
    1. Brobst DE,
    2. Ding X,
    3. Creech KL,
    4. Goodwin B,
    5. Kelley B, and
    6. Staudinger JL
    (2004) Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 310:528–535.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Buckley DB and
    2. Klaassen CD
    (2009) Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. Drug Metab Dispos 37:847–856.
    OpenUrlAbstract/FREE Full Text
    1. Burk O,
    2. Koch I,
    3. Raucy J,
    4. Hustert E,
    5. Eichelbaum M,
    6. Brockmöller J,
    7. Zanger UM, and
    8. Wojnowski L.
    The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (P XR) and constitutively activated receptor (CAR). J Biol Chem. 2004 Sep 10;279(37):38379–85.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Burk O,
    2. Arnold KA,
    3. Nussler AK,
    4. Schaeffeler E,
    5. Efimova E,
    6. Avery BA,
    7. Avery MA,
    8. Fromm MF, and
    9. Eichelbaum M
    (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954–1965.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Cantoni L,
    2. Rozio M,
    3. Mangolini A,
    4. Hauri L, and
    5. Caccia S
    (2003) Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 75:25–30.
    OpenUrlCrossRefPubMed
    1. Caparrós-Martín JA,
    2. Lareu RR,
    3. Ramsay JP,
    4. Peplies J,
    5. Reen FJ,
    6. Headlam HA,
    7. Ward NC,
    8. Croft KD,
    9. Newsholme P,
    10. Hughes JD, et al.
    (2017) Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5:95.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Chang TK and
    2. Waxman DJ
    (2006) Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51–73.
    OpenUrlCrossRefPubMed
    1. Chen T.
    Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev. 2010 Oct 30;62(13):1257–64.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Cheng J,
    2. Shah YM, and
    3. Gonzalez FJ
    (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 33:323–330.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Cheng SL,
    2. Li X,
    3. Lehmler HJ,
    4. Phillips B,
    5. Shen D, and
    6. Cui JY
    (2018) Gut microbiota modulates interactions between polychlorinated biphenyls and bile acid homeostasis. Toxicol Sci 166:269–287.
    OpenUrl
  22. ↵
    1. Cheng X,
    2. Maher J,
    3. Dieter MZ, and
    4. Klaassen CD
    (2005) Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab Dispos 33:1276–1282.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Conly JM and
    2. Stein K
    (1992) The production of menaquinones (vitamin K2) by intestinal bacteria and their role in maintaining coagulation homeostasis. Prog Food Nutr Sci 16:307–343.
    OpenUrlPubMed
    1. Cooper BW,
    2. Cho T M,
    3. Thompson P M, and
    4. Wallace AD.
    Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of P XR expression. Toxicol Sci. 2008 Jun;103(2):268–77.
    OpenUrlCrossRefPubMed
    1. Coumoul X,
    2. Diry M, and
    3. Barouki R.
    P XRdependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem Pharmacol. 2002 Nov 15;64(10):1513-9.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Creusot N,
    2. Garoche C,
    3. Grimaldi M,
    4. Boulahtouf A,
    5. Chiavarina B,
    6. Bourguet W, and
    7. Balaguer P
    (2021) A comparative study of human and zebrafish pregnane X receptor activities of pesticides and steroids using in vitro reporter gene assays. Front Endocrinol (Lausanne) 12:665521.
    OpenUrl
  25. ↵
    1. Cruz R,
    2. Palmeira JD,
    3. Martins ZE,
    4. Faria MA,
    5. Ferreira H,
    6. Marques A,
    7. Casal S, and
    8. Cunha SC
    (2020) Multidisciplinary approach to determine the effect of polybrominated diphenyl ethers on gut microbiota. Environ Pollut 260:113920.
    OpenUrl
  26. ↵
    1. Cui H,
    2. Gu X,
    3. Chen J,
    4. Xie Y,
    5. Ke S,
    6. Wu J,
    7. Golovko A,
    8. Morpurgo B,
    9. Yan C,
    10. Phillips TD, et al.
    (2017) Pregnane X receptor regulates the AhR/Cyp1A1 pathway and protects liver cells from benzo-[α]-pyrene-induced DNA damage. Toxicol Lett 275:67–76.
    OpenUrl
  27. ↵
    1. Cui JY,
    2. Gunewardena SS,
    3. Rockwell CE, and
    4. Klaassen CD
    (2010) ChIPing the cistrome of PXR in mouse liver. Nucleic Acids Res 38:7943–7963.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Cui JY,
    2. Renaud HJ, and
    3. Klaassen CD
    (2012) Ontogeny of novel cytochrome P450 gene isoforms during postnatal liver maturation in mice. Drug Metab Dispos 40:1226–1237.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Daujat-Chavanieu M and
    2. Gerbal-Chaloin S
    (2020) Regulation of CAR and PXR expression in health and disease. Cells 9:2395.
    OpenUrl
  30. ↵
    1. Dempsey JL and
    2. Cui JY
    (2019) Microbiome is a functional modifier of P450 drug metabolism. Curr Pharmacol Rep 5:481–490.
    OpenUrl
  31. ↵
    1. Dempsey JL,
    2. Wang D,
    3. Siginir G,
    4. Fei Q,
    5. Raftery D,
    6. Gu H, and
    7. Yue Cui J
    (2019) Pharmacological activation of PXR and CAR downregulates distinct bile acid-metabolizing intestinal bacteria and alters bile acid homeostasis. Toxicol Sci 168:40–60.
    OpenUrlCrossRef
    1. Deng R,
    2. Xu C,
    3. Chen X,
    4. Chen P,
    5. Wang Y,
    6. Zhou X,
    7. Jin J,
    8. Niu L,
    9. Ying M,
    10. Huang M, and
    11. Bi H.
    Resveratrol suppresses the inducible expression of CYP3A4 through the pregnane X receptor. J Pharmacol Sci. 2014;126(2):146–54.
    OpenUrl
  32. ↵
    1. Derrien M,
    2. Belzer C, and
    3. de Vos WM
    (2017) Akkermansia muciniphila and its role in regulating host functions. Microb Pathog 106:171–181.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Desai PB,
    2. Nallani SC,
    3. Sane RS,
    4. Moore LB,
    5. Goodwin BJ,
    6. Buckley DJ, and
    7. Buckley AR
    (2002) Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 30:608–612.
    OpenUrlAbstract/FREE Full Text
    1. Ding X,
    2. Lichti K, and
    3. Staudinger JL.
    The mycoestrogen zearalenone induces CYP3A through activation of the pregnane X receptor. Toxicol Sci. 2006 Jun;91(2):448–55.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Ding X and
    2. Staudinger JL
    (2005a) Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther 312:849–856.
    OpenUrlAbstract/FREE Full Text
    1. Ding X and
    2. Staudinger JL
    (2005b) The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. J Pharmacol Exp Ther 314(1):120–7.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Doricakova A and
    2. Vrzal R
    (2015) A food contaminant ochratoxin A suppresses pregnane X receptor (PXR)-mediated CYP3A4 induction in primary cultures of human hepatocytes. Toxicology 337:72–78.
    OpenUrl
  36. ↵
    1. Dou W,
    2. Zhang J,
    3. Li H,
    4. Kortagere S,
    5. Sun K,
    6. Ding L,
    7. Ren G,
    8. Wang Z, and
    9. Mani S
    (2014) Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J Nutr Biochem 25:923–933.
    OpenUrlCrossRefPubMed
    1. Dürr D,
    2. Stieger B,
    3. Kullak-Ublick GA,
    4. Rentsch KM,
    5. Steinert HC,
    6. Meier PJ, and
    7. Fattinger K
    (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Dvořák Z,
    2. Kopp F,
    3. Costello CM,
    4. Kemp JS,
    5. Li H,
    6. Vrzalová A,
    7. Štěpánková M,
    8. Bartoňková I,
    9. Jiskrová E,
    10. Poulíková K, et al.
    (2020a) Targeting the pregnane X receptor using microbial metabolite mimicry. EMBO Mol Med 12:e11621.
    OpenUrl
  38. ↵
    1. Dvořák Z,
    2. Sokol H, and
    3. Mani S
    (2020b) Drug mimicry: promiscuous receptors PXR and AhR, and microbial metabolite interactions in the intestine. Trends Pharmacol Sci 41:900–908.
    OpenUrl
    1. Dybdahl M,
    2. Nikolov NG,
    3. Wedebye EB,
    4. Jónsdóttir SÓ, and
    5. Niemelä JR.
    QSAR model for human pregnane X receptor (P XR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):301–9.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Eaton DL and
    2. Klaassen CD
    (1979) Effects of microsomal enzyme inducers on carrier-mediated transport systems in isolated rat hepatocytes. J Pharmacol Exp Ther 208:381–385.
    OpenUrlPubMed
    1. Egusquiza RJ,
    2. Ambrosio ME,
    3. Wang SG,
    4. Kay KM,
    5. Zhang C,
    6. Lehmler HJ, and
    7. Blumberg B.
    Evaluating the Role of the Steroid and Xenobiotic Receptor (SXR/P XR) in P CB-153 Metabolism and Protection against Associated Adverse Effects during Perinatal and Chronic Exposure in Mice. Environ Health Perspect. 2020 Apr;128(4):47011.
    OpenUrl
  40. ↵
    1. Ekins S,
    2. Reschly EJ,
    3. Hagey LR, and
    4. Krasowski MD
    (2008) Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol 8:103.
    OpenUrlCrossRefPubMed
  41. ↵
    1. El-Sankary W,
    2. Gibson GG,
    3. Ayrton A, and
    4. Plant N
    (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499–1504.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Fickert P,
    2. Fuchsbichler A,
    3. Marschall HU,
    4. Wagner M,
    5. Zollner G,
    6. Krause R,
    7. Zatloukal K,
    8. Jaeschke H,
    9. Denk H, and
    10. Trauner M
    (2006) Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 168:410–422.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Foley MH,
    2. O’Flaherty S,
    3. Barrangou R, and
    4. Theriot CM
    (2019) Bile salt hydrolases: Gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. PLoS Pathog 15:e1007581.
    OpenUrlCrossRef
  44. ↵
    1. Fu ZD,
    2. Csanaky IL, and
    3. Klaassen CD
    (2012) Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice. Drug Metab Dispos 40:1216–1225.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Fu ZD,
    2. Selwyn FP,
    3. Cui JY, and
    4. Klaassen CD
    (2017) RNA-Seq profiling of intestinal expression of xenobiotic processing genes in germ-free mice. Drug Metab Dispos 45:1225–1238.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Gibson GG,
    2. Plant NJ,
    3. Swales KE,
    4. Ayrton A, and
    5. El-Sankary W
    (2002) Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165–206.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Giebel NL,
    2. Shadley JD,
    3. McCarver DG,
    4. Dorko K,
    5. Gramignoli R,
    6. Strom SC,
    7. Yan K,
    8. Simpson PM, and
    9. Hines RN
    (2016) Role of chromatin structural changes in regulating human CYP3A ontogeny. Drug Metab Dispos 44:1027–1037.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Gomez MV,
    2. Dutta M,
    3. Suvorov A,
    4. Shi X,
    5. Gu H,
    6. Mani S, and
    7. Yue Cui J
    (2021) Early life exposure to environmental contaminants (BDE-47, TBBPA, and BPS) produced persistent alterations in fecal microbiome in adult male mice. Toxicol Sci 179:14–30.
    OpenUrl
  49. ↵
    1. Guzelian J,
    2. Barwick JL,
    3. Hunter L,
    4. Phang TL,
    5. Quattrochi LC, and
    6. Guzelian PS
    (2006) Identification of genes controlled by the pregnane X receptor by microarray analysis of mRNAs from pregnenolone 16alpha-carbonitrile-treated rats. Toxicol Sci 94:379–387.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Hart SN,
    2. Cui Y,
    3. Klaassen CD, and
    4. Zhong XB
    (2009) Three patterns of cytochrome P450 gene expression during liver maturation in mice. Drug Metab Dispos 37:116–121.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. He J,
    2. Gao J,
    3. Xu M,
    4. Ren S,
    5. Stefanovic-Racic M,
    6. O’Doherty RM, and
    7. Xie W
    (2013) PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes 62:1876–1887.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. He L,
    2. Li H,
    3. Huang N,
    4. Zhou X,
    5. Tian J,
    6. Li T,
    7. Wu J,
    8. Tian Y,
    9. Yin Y, and
    10. Yao K
    (2017) Alpha-ketoglutarate suppresses the NF-κB-mediated inflammatory pathway and enhances the PXR-regulated detoxification pathway. Oncotarget 8:102974–102988.
    OpenUrl
  53. ↵
    1. Hernandez JP,
    2. Mota LC, and
    3. Baldwin WS
    (2009) Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med 7:81–105.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Hoffart E,
    2. Ghebreghiorghis L,
    3. Nussler AK,
    4. Thasler WE,
    5. Weiss TS,
    6. Schwab M, and
    7. Burk O
    (2012) Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor. Br J Pharmacol 165:1595–1608.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Howe K,
    2. Sanat F,
    3. Thumser AE,
    4. Coleman T, and
    5. Plant N
    (2011) The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica 41:519–529.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Huang H,
    2. Wang H,
    3. Sinz M,
    4. Zoeckler M,
    5. Staudinger J,
    6. Redinbo MR,
    7. Teotico DG,
    8. Locker J,
    9. Kalpana GV, and
    10. Mani S
    (2007) Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26:258–268.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Huang K,
    2. Mukherjee S,
    3. DesMarais V,
    4. Albanese JM,
    5. Rafti E,
    6. Draghi Ii A,
    7. Maher LA,
    8. Khanna KM,
    9. Mani S, and
    10. Matson AP
    (2018) Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitis. Pediatr Res 83:1031–1040.
    OpenUrl
  58. ↵
    1. Hukkanen J,
    2. Hakkola J, and
    3. Rysä J
    (2014) Pregnane X receptor (PXR)—a contributor to the diabetes epidemic? Drug Metabol Drug Interact 29:3–15.
    OpenUrl
    1. Hurst CH and
    2. Waxman DJ.
    Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):266–74.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Ishii M,
    2. Toda T,
    3. Ikarashi N,
    4. Kusunoki Y,
    5. Kon R,
    6. Ochiai W,
    7. Machida Y, and
    8. Sugiyama K
    (2014) Gastrectomy increases the expression of hepatic cytochrome P450 3A by increasing lithocholic acid-producing enteric bacteria in mice. Biol Pharm Bull 37:298–305.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Jacobs MN,
    2. Nolan GT, and
    3. Hood SR
    (2005) Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol 209:123–133.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Jia B and
    2. Jeon CO
    (2019) Promotion and induction of liver cancer by gut microbiome-mediated modulation of bile acids. PLoS Pathog 15:e1007954.
    OpenUrl
  62. ↵
    1. Jones SA,
    2. Moore LB,
    3. Shenk JL,
    4. Wisely GB,
    5. Hamilton GA,
    6. McKee DD,
    7. Tomkinson NC,
    8. LeCluyse EL,
    9. Lambert MH,
    10. Willson TM, et al.
    (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Jung D,
    2. Mangelsdorf DJ, and
    3. Meyer UA
    (2006) Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 281:19081–19091.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Kahan BD,
    2. Kramer WG,
    3. Wideman C,
    4. Flechner SM,
    5. Lorber MI, and
    6. Van Buren CT
    (1986) Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41:459–464.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Kim S,
    2. Choi S,
    3. Dutta M,
    4. Asubonteng JO,
    5. Polunas M,
    6. Goedken M,
    7. Gonzalez FJ,
    8. Cui JY, and
    9. Gyamfi MA
    (2021) Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity- and inflammation-prone gut microbiome signature. Biochem Pharmacol 193:114698 10.1016/j.bcp.2021.114698.
    OpenUrl
  66. ↵
    1. Klaassen CD
    (1972) Immaturity of the newborn rat’s hepatic excretory function for ouabain. J Pharmacol Exp Ther 183:520–526.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Klaassen CD
    (1973) Comparison of the toxicity of chemicals in newborn rats to bile duct-ligated and sham-operated rats and mice. Toxicol Appl Pharmacol 24:37–44.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Klaassen CD
    (1974a) Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides. J Pharmacol Exp Ther 191:201–211.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Klaassen CD
    (1974b) Stimulation of the development of the hepatic excretory mechanism for ouabain in newborn rats with microsomal enzyme inducers. J Pharmacol Exp Ther 191:212–218.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Kliewer SA,
    2. Goodwin B, and
    3. Willson TM
    (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687–702.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Kliewer SA,
    2. Moore JT,
    3. Wade L,
    4. Staudinger JL,
    5. Watson MA,
    6. Jones SA,
    7. McKee DD,
    8. Oliver BB,
    9. Willson TM,
    10. Zetterström RH, et al.
    (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82.
    OpenUrlCrossRefPubMed
    1. Kliewer SA.
    Nuclear receptor P XR: discovery of a pharmaceutical anti-target. J Clin Invest. 2015 Apr;125(4):1388–9.
    OpenUrl
  72. ↵
    1. Kolodkin A,
    2. Sahin N,
    3. Phillips A,
    4. Hood SR,
    5. Bruggeman FJ,
    6. Westerhoff HV, and
    7. Plant N
    (2013) Optimization of stress response through the nuclear receptor-mediated cortisol signalling network. Nat Commun 4:1792 10.1038/ncomms2799.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Komoroski BJ,
    2. Zhang S,
    3. Cai H,
    4. Hutzler JM,
    5. Frye R,
    6. Tracy TS,
    7. Strom SC,
    8. Lehmann T,
    9. Ang CY,
    10. Cui YY, et al.
    (2004) Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32:512–518.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Kostrubsky VE,
    2. Lewis LD,
    3. Strom SC,
    4. Wood SG,
    5. Schuetz EG,
    6. Schuetz JD,
    7. Sinclair PR,
    8. Wrighton SA, and
    9. Sinclair JF
    (1998) Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 355:131–136.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Krasowski MD,
    2. Ni A,
    3. Hagey LR, and
    4. Ekins S
    (2011) Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol 334:39–48.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Krecic-Shepard ME,
    2. Park K,
    3. Barnas C,
    4. Slimko J,
    5. Kerwin DR, and
    6. Schwartz JB
    (2000) Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 68:130–142.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Kumar R,
    2. Litoff EJ,
    3. Boswell WT, and
    4. Baldwin WS
    (2018) High fat diet induced obesity is mitigated in Cyp3a-null female mice. Chem Biol Interact 289:129–140.
    OpenUrl
  78. ↵
    1. Kurihara I,
    2. Lee DK,
    3. Petit FG,
    4. Jeong J,
    5. Lee K,
    6. Lydon JP,
    7. DeMayo FJ,
    8. Tsai MJ, and
    9. Tsai SY
    (2007) COUP-TFII mediates progesterone regulation of uterine implantation by controlling ER activity. PLoS Genet 3:e102.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Landes N,
    2. Pfluger P,
    3. Kluth D,
    4. Birringer M,
    5. Rühl R,
    6. Böl GF,
    7. Glatt H, and
    8. Brigelius-Flohé R
    (2003) Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 65:269–273.
    OpenUrlCrossRefPubMed
  80. ↵
    1. LeCluyse EL
    (2001) Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 134:283–289.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Lehmann JM,
    2. McKee DD,
    3. Watson MA,
    4. Willson TM,
    5. Moore JT, and
    6. Kliewer SA
    (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023.
    OpenUrlCrossRefPubMed
    1. Lemaire G,
    2. de Sousa G, and
    3. Rahmani R.
    A P XR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem Pharmacol. 2004 Dec 15;68(12):2347–58.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Lemaire G,
    2. Mnif W,
    3. Pascussi JM,
    4. Pillon A,
    5. Rabenoelina F,
    6. Fenet H,
    7. Gomez E,
    8. Casellas C,
    9. Nicolas JC,
    10. Cavaillès V, et al.
    (2006) Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol Sci 91:501–509.
    OpenUrlCrossRefPubMed
  83. ↵
    1. Li CY,
    2. Cheng SL,
    3. Bammler TK, and
    4. Cui JY
    (2016a) Editor’s highlight: Neonatal activation of the xenobiotic-sensors PXR and CAR results in acute and persistent down-regulation of PPARα-signaling in mouse liver. Toxicol Sci 153:282–302.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Li CY,
    2. Dempsey JL,
    3. Wang D,
    4. Lee S,
    5. Weigel KM,
    6. Fei Q,
    7. Bhatt DK,
    8. Prasad B,
    9. Raftery D,
    10. Gu H, et al.
    (2018) PBDEs altered gut microbiome and bile acid homeostasis in male C57BL/6 mice. Drug Metab Dispos 46:1226–1240.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Li CY,
    2. Lee S,
    3. Cade S,
    4. Kuo LJ,
    5. Schultz IR,
    6. Bhatt DK,
    7. Prasad B,
    8. Bammler TK, and
    9. Cui JY
    (2017) Novel interactions between gut microbiome and host drug-processing genes modify the hepatic metabolism of the environmental chemicals polybrominated diphenyl ethers. Drug Metab Dispos 45:1197–1214.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Li CY,
    2. Renaud HJ,
    3. Klaassen CD, and
    4. Cui JY
    (2016b) Age-specific regulation of drug-processing genes in mouse liver by ligands of xenobiotic-sensing transcription factors. Drug Metab Dispos 44:1038–1049.
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Li H,
    2. Illés P,
    3. Karunaratne CV,
    4. Nordstrøm LU,
    5. Luo X,
    6. Yang A,
    7. Qiu Y,
    8. Kurland IJ,
    9. Lukin DJ,
    10. Chen W, et al.
    (2021) Deciphering structural bases of intestinal and hepatic selectivity in targeting pregnane X receptor with indole-based microbial mimics. Bioorg Chem 109:104661 10.1016/j.bioorg.2021.104661.
    OpenUrl
    1. Li L,
    2. Welch MA,
    3. Li Z,
    4. Mackowiak B,
    5. Heyward S,
    6. Swaan PW, and
    7. Wang H.
    Mechanistic Insights of Phenobarbital-Mediated Activation of Human but Not Mouse Pregnane X Receptor. Mol Pharmacol. 2019 Sep;96(3):345–354. doi: 10.1124/mol.119.116616. Epub 2019 Jul 10. P MID: 31436536; P MCID: P MC6701513.
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Li L,
    2. Li ZQ,
    3. Deng CH,
    4. Ning MR,
    5. Li HQ,
    6. Bi SS,
    7. Zhou TY, and
    8. Lu W
    (2012) A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. Acta Pharmacol Sin 33:127–136.
    OpenUrlPubMed
  89. ↵
    1. Li T and
    2. Chiang JY
    (2005) Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol 288:G74–G84.
    OpenUrlCrossRefPubMed
  90. ↵
    1. Li T and
    2. Chiang JY
    (2006) Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34:756–764.
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Li T and
    2. Chiang JY
    (2015) Bile acids as metabolic regulators. Curr Opin Gastroenterol 31:159–165.
    OpenUrlCrossRefPubMed
  92. ↵
    1. Li Y,
    2. Cui Y,
    3. Hart SN,
    4. Klaassen CD, and
    5. Zhong XB
    (2009) Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol Pharmacol 75:1171–1179.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    1. Lim JJ,
    2. Li X,
    3. Lehmler HJ,
    4. Wang D,
    5. Gu H, and
    6. Cui JY
    (2020) Gut microbiome critically impacts PCB-induced changes in metabolic fingerprints and the hepatic transcriptome in mice. Toxicol Sci 177:168–187.
    OpenUrl
    1. Lin W,
    2. Bwayi M,
    3. Wu J,
    4. Li Y,
    5. Chai SC,
    6. Huber AD, and
    7. Chen T.
    CIT CO Directly Binds to and Activates Human Pregnane X Receptor. Mol Pharmacol. 2020 Mar;97(3):180–190.
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Lin W,
    2. Wang YM,
    3. Chai SC,
    4. Lv L,
    5. Zheng J,
    6. Wu J,
    7. Zhang Q,
    8. Wang YD,
    9. Griffin PR, and
    10. Chen T
    (2017) SPA70 is a potent antagonist of human pregnane X receptor. Nat Commun 8:741.
    OpenUrl
    1. Lindley C,
    2. Hamilton G,
    3. McCune JS,
    4. Faucette S,
    5. Shord SS,
    6. Hawke RL,
    7. Wang H,
    8. Gilbert D,
    9. Jolley S,
    10. Yan B, and
    11. LeCluyse EL.
    The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814–22.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Little M,
    2. Dutta M,
    3. Li H,
    4. Matson A,
    5. Shi X,
    6. Mascarinas G,
    7. Molla B,
    8. Weigel K,
    9. Gu H,
    10. Mani S, et al.
    (2021) Understanding the physiological functions of the host xenobiotic-sensing nuclear receptors PXR and CAR on the gut microbiome using genetically modified mice. Acta Pharm Sin B, in press 10.1016/j.aspb.2021.07.022.
  96. ↵
    1. Liu G,
    2. Tian J,
    3. Yin H,
    4. Yin J, and
    5. Tang Y
    (2019) Self-protective transcriptional alterations in ZF4 cells exposed to Pb(NO3 )2 and AgNO3. J Biochem Mol Toxicol 33:e22408.
    OpenUrl
  97. ↵
    1. Lu YF,
    2. Jin T,
    3. Xu Y,
    4. Zhang D,
    5. Wu Q,
    6. Zhang YK, and
    7. Liu J
    (2013) Sex differences in the circadian variation of cytochrome p450 genes and corresponding nuclear receptors in mouse liver. Chronobiol Int 30:1135–1143.
    OpenUrlCrossRefPubMed
  98. ↵
    1. Luke NS,
    2. DeVito MJ,
    3. Shah I, and
    4. El-Masri HA
    (2010) Development of a quantitative model of pregnane X receptor (PXR) mediated xenobiotic metabolizing enzyme induction. Bull Math Biol 72:1799–1819.
    OpenUrlPubMed
  99. ↵
    1. Luo G,
    2. Cunningham M,
    3. Kim S,
    4. Burn T,
    5. Lin J,
    6. Sinz M,
    7. Hamilton G,
    8. Rizzo C,
    9. Jolley S,
    10. Gilbert D, et al.
    (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Lynch C,
    2. Sakamuru S,
    3. Huang R,
    4. Niebler J,
    5. Ferguson SS, and
    6. Xia M
    (2021) Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library. Biochem Pharmacol 184:114368 10.1016/j.bcp.2020.114368.
    OpenUrl
  101. ↵
    1. Ma X,
    2. Idle JR, and
    3. Gonzalez FJ
    (2008) The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 4:895–908.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Ma Y,
    2. Sachdeva K,
    3. Liu J,
    4. Ford M,
    5. Yang D,
    6. Khan IA,
    7. Chichester CO, and
    8. Yan B
    (2004) Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos 32:1317–1324.
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Maher JM,
    2. Cheng X,
    3. Slitt AL,
    4. Dieter MZ, and
    5. Klaassen CD
    (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 33:956–962.
    OpenUrlAbstract/FREE Full Text
    1. Mani S,
    2. Dou W, and
    3. Redinbo MR.
    P XR antagonists and implication in drug metabolism. Drug Metab Rev. 2013 Feb;45(1):60–72.
    OpenUrlCrossRefPubMed
  104. ↵
    1. Marek CJ,
    2. Tucker SJ,
    3. Konstantinou DK,
    4. Elrick LJ,
    5. Haefner D,
    6. Sigalas C,
    7. Murray GI,
    8. Goodwin B, and
    9. Wright MC
    (2005) Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem J 387:601–608.
    OpenUrlAbstract/FREE Full Text
    1. Medina-Díaz IM,
    2. Estrada-Muñiz E,
    3. Reyes-Hernández OD,
    4. Ramírez P,
    5. Vega L, and
    6. Elizondo G
    (2009) Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. Toxicol Appl Pharmacol 239:162–168.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Meucci V and
    2. Arukwe A
    (2006) The xenoestrogen 4-nonylphenol modulates hepatic gene expression of pregnane X receptor, aryl hydrocarbon receptor, CYP3A and CYP1A1 in juvenile Atlantic salmon (Salmo salar). Comp Biochem Physiol C Toxicol Pharmacol 142:142–150.
    OpenUrlCrossRefPubMed
  106. ↵
    1. Mikamo E,
    2. Harada S,
    3. Nishikawa J, and
    4. Nishihara T
    (2003) Endocrine disruptors induce cytochrome P450 by affecting transcriptional regulation via pregnane X receptor. Toxicol Appl Pharmacol 193:66–72.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Milnes MR,
    2. Garcia A,
    3. Grossman E,
    4. Grün F,
    5. Shiotsugu J,
    6. Tabb MM,
    7. Kawashima Y,
    8. Katsu Y,
    9. Watanabe H,
    10. Iguchi T, et al.
    (2008) Activation of steroid and xenobiotic receptor (SXR, NR1I2) and its orthologs in laboratory, toxicologic, and genome model species. Environ Health Perspect 116:880–885.
    OpenUrlCrossRefPubMed
    1. Mohandas S and
    2. Vairappan B.
    Role of pregnane X-receptor in regulating bacterial translocation in chronic liver diseases. World J Hepatol. 2017 Nov 18;9(32):1210–1226.
    OpenUrl
  108. ↵
    1. Moore JT and
    2. Kliewer SA
    (2000) Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1–10.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Moore JT,
    2. Moore LB,
    3. Maglich JM, and
    4. Kliewer SA
    (2003) Functional and structural comparison of PXR and CAR. Biochim Biophys Acta 1619:235–238.
    OpenUrlPubMed
    1. Moore LB,
    2. Parks DJ,
    3. Jones SA,
    4. Bledsoe RK,
    5. Consler TG,
    6. Stimmel JB,
    7. Goodwin B,
    8. Liddle C,
    9. Blanchard SG,
    10. Willson TM, et al.
    (2000a) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122–15127.
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Moore LB,
    2. Goodwin B,
    3. Jones SA,
    4. Wisely GB,
    5. Serabjit-Singh CJ,
    6. Willson TM,
    7. Collins JL, and
    8. Kliewer SA
    (2000b) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502.
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Morgan ET,
    2. Dempsey JL,
    3. Mimche SM,
    4. Lamb TJ,
    5. Kulkarni S,
    6. Cui JY,
    7. Jeong H, and
    8. Slitt AL
    (2018) Physiological regulation of drug metabolism and transport: pregnancy, microbiome, inflammation, infection, and fasting. Drug Metab Dispos 46:503–513.
    OpenUrlAbstract/FREE Full Text
  112. ↵
    1. Newman SL and
    2. Guzelian PS
    (1983) Identification of the cyanopregnenolone-inducible form of hepatic cytochrome P-450 as a catalyst of aldrin epoxidation. Biochem Pharmacol 32:1529–1531.
    OpenUrlCrossRefPubMed
  113. ↵
    1. Ngan CH,
    2. Beglov D,
    3. Rudnitskaya AN,
    4. Kozakov D,
    5. Waxman DJ, and
    6. Vajda S
    (2009) The structural basis of pregnane X receptor binding promiscuity. Biochemistry 48:11572–11581.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Noble SM,
    2. Carnahan VE,
    3. Moore LB,
    4. Luntz T,
    5. Wang H,
    6. Ittoop OR,
    7. Stimmel JB,
    8. Davis-Searles PR,
    9. Watkins RE,
    10. Wisely GB, et al.
    (2006) Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 45:8579–8589.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Ourlin JC,
    2. Lasserre F,
    3. Pineau T,
    4. Fabre JM,
    5. Sa-Cunha A,
    6. Maurel P,
    7. Vilarem MJ, and
    8. Pascussi JM
    (2003) The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol 17:1693–1703.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Pacyniak EK,
    2. Cheng X,
    3. Cunningham ML,
    4. Crofton K,
    5. Klaassen CD, and
    6. Guo GL
    (2007) The flame retardants, polybrominated diphenyl ethers, are pregnane X receptor activators. Toxicol Sci 97:94–102.
    OpenUrlCrossRefPubMed
  117. ↵
    1. Parkinson A,
    2. Mudra DR,
    3. Johnson C,
    4. Dwyer A, and
    5. Carroll KM
    (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209.
    OpenUrlCrossRefPubMed
    1. Pascussi JM,
    2. Drocourt L,
    3. Fabre JM,
    4. Maurel P, and
    5. Vilarem MJ.
    Dexamethasone induces pregnane X receptor and retinoid X receptoralpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol. 2000 Aug;58(2):361–72.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Pascussi JM,
    2. Drocourt L,
    3. Gerbal-Chaloin S,
    4. Fabre JM,
    5. Maurel P, and
    6. Vilarem MJ
    (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346–6358.
    OpenUrlPubMed
  119. ↵
    1. Petrick JS and
    2. Klaassen CD
    (2007) Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport. Drug Metab Dispos 35:1806–1815.
    OpenUrlAbstract/FREE Full Text
  120. ↵
    1. Pinne M,
    2. Ponce E, and
    3. Raucy JL
    (2016) Transactivation assays to assess canine and rodent pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation. PLoS One 11:e0164642.
    OpenUrl
  121. ↵
    1. Png CW,
    2. Lindén SK,
    3. Gilshenan KS,
    4. Zoetendal EG,
    5. McSweeney CS,
    6. Sly LI,
    7. McGuckin MA, and
    8. Florin TH
    (2010) Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105:2420–2428.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Pulakazhi Venu VK,
    2. Saifeddine M,
    3. Mihara K,
    4. Tsai YC,
    5. Nieves K,
    6. Alston L,
    7. Mani S,
    8. McCoy KD,
    9. Hollenberg MD, and
    10. Hirota SA
    (2019) The pregnane X receptor and its microbiota-derived ligand indole 3-propionic acid regulate endothelium-dependent vasodilation. Am J Physiol Endocrinol Metab 317:E350–E361.
    OpenUrl
  123. ↵
    1. Raucy J,
    2. Warfe L,
    3. Yueh MF, and
    4. Allen SW
    (2002) A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther 303:412–423.
    OpenUrlAbstract/FREE Full Text
  124. ↵
    1. Raucy JL
    (2003) Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533–539.
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Ravussin Y,
    2. Koren O,
    3. Spor A,
    4. LeDuc C,
    5. Gutman R,
    6. Stombaugh J,
    7. Knight R,
    8. Ley RE, and
    9. Leibel RL
    (2012) Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring) 20:738–747.
    OpenUrlCrossRefPubMed
  126. ↵
    1. Reschly EJ,
    2. Bainy AC,
    3. Mattos JJ,
    4. Hagey LR,
    5. Bahary N,
    6. Mada SR,
    7. Ou J,
    8. Venkataramanan R, and
    9. Krasowski MD
    (2007) Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol 7:222.
    OpenUrlCrossRefPubMed
    1. Ren H,
    2. Vallanat B,
    3. Nelson DM,
    4. Yeung LWY,
    5. Guruge KS,
    6. Lam P KS,
    7. Lehman-McKeeman LD, and
    8. Corton JC.
    Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod Toxicol. 2009 Jun;27(3-4):266–277.
    OpenUrlCrossRefPubMed
  127. ↵
    1. Reschly EJ and
    2. Krasowski MD
    (2006) Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 7:349–365.
    OpenUrlCrossRefPubMed
  128. ↵
    1. Saraswathi V,
    2. Perriotte-Olson C,
    3. Ganesan M,
    4. Desouza CV,
    5. Alnouti Y,
    6. Duryee MJ,
    7. Thiele GM,
    8. Nordgren TM, and
    9. Clemens DL
    (2017) A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. J Nutr Biochem 42:149–159.
    OpenUrl
  129. ↵
    1. Scandlyn MJ,
    2. Stuart EC, and
    3. Rosengren RJ
    (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4:413–424.
    OpenUrlCrossRefPubMed
  130. ↵
    1. Schmidt R,
    2. Baumann F,
    3. Hanschmann H,
    4. Geissler F, and
    5. Preiss R
    (2001) Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 26:193–200.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Schuetz E,
    2. Lan L,
    3. Yasuda K,
    4. Kim R,
    5. Kocarek TA,
    6. Schuetz J, and
    7. Strom S
    (2002) Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62:439–445.
    OpenUrlAbstract/FREE Full Text
  132. ↵
    1. Schuetz EG,
    2. Wrighton SA,
    3. Barwick JL, and
    4. Guzelian PS
    (1984) Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de novo synthesis of a common form of cytochrome P-450 in cultures of adult rat hepatocytes and in the liver in vivo. J Biol Chem 259:1999–2006.
    OpenUrlAbstract/FREE Full Text
  133. ↵
    1. Scoville DK,
    2. Li CY,
    3. Wang D,
    4. Dempsey JL,
    5. Raftery D,
    6. Mani S,
    7. Gu H, and
    8. Cui JY
    (2019) Polybrominated diphenyl ethers and gut microbiome modulate metabolic syndrome-related aqueous metabolites in mice. Drug Metab Dispos 47:928–940.
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Seamon KB,
    2. Padgett W, and
    3. Daly JW
    (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 78:3363–3367.
    OpenUrlAbstract/FREE Full Text
  135. ↵
    1. Selwyn FP,
    2. Cheng SL,
    3. Bammler TK,
    4. Prasad B,
    5. Vrana M,
    6. Klaassen C, and
    7. Cui JY
    (2015a) Developmental regulation of drug-processing genes in livers of germ-free mice. Toxicol Sci 147:84–103.
    OpenUrlCrossRefPubMed
  136. ↵
    1. Selwyn FP,
    2. Cheng SL,
    3. Klaassen CD, and
    4. Cui JY
    (2016) Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics. Drug Metab Dispos 44:262–274.
    OpenUrlAbstract/FREE Full Text
  137. ↵
    1. Selwyn FP,
    2. Cui JY, and
    3. Klaassen CD
    (2015b) RNA-Seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab Dispos 43:1572–1580.
    OpenUrlAbstract/FREE Full Text
  138. ↵
    1. Shehu AI,
    2. Li G,
    3. Xie W, and
    4. Ma X
    (2016) The pregnane X receptor in tuberculosis therapeutics. Expert Opin Drug Metab Toxicol 12:21–30.
    OpenUrlCrossRefPubMed
    1. Shehu AI,
    2. Lu J,
    3. Wang P,
    4. Zhu J,
    5. Wang Y,
    6. Yang D,
    7. McMahon D,
    8. Xie W,
    9. Gonzalez FJ, and
    10. Ma X.
    Pregnane X receptor activation potentiates ritonavir hepatotoxicity. J Clin Invest. 2019 Apr 30;129(7):2898–2903.
    OpenUrl
    1. Shen Y,
    2. Shi Z,
    3. Fan JT, and
    4. Yan B.
    Dechlorination and demethylation of ochratoxin A enhance blocking activity of P XR activation, suppress P XR expression and reduce cytotoxicity. Toxicol Lett. 2020 Oct 10;332:171–180.
    OpenUrl
    1. Shi D,
    2. Yang D, and
    3. Yan B.
    Dexamethasone transcriptionally increases the expression of the pregnane X receptor and synergistically enhances pyrethroid esfenvalerate in the induction of cytochrome P450 3A23. Biochem Pharmacol. 2010 Oct 15;80(8):1274–83.
    OpenUrlCrossRefPubMed
  139. ↵
    1. Shukla SJ,
    2. Sakamuru S,
    3. Huang R,
    4. Moeller TA,
    5. Shinn P,
    6. Vanleer D,
    7. Auld DS,
    8. Austin CP, and
    9. Xia M
    (2011) Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos 39:151–159.
    OpenUrl
  140. ↵
    1. Smirlis D,
    2. Muangmoonchai R,
    3. Edwards M,
    4. Phillips IR, and
    5. Shephard EA
    (2001) Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics. J Biol Chem 276:12822–12826.
    OpenUrlAbstract/FREE Full Text
  141. ↵
    1. Smith RP,
    2. Eckalbar WL,
    3. Morrissey KM,
    4. Luizon MR,
    5. Hoffmann TJ,
    6. Sun X,
    7. Jones SL,
    8. Force Aldred S,
    9. Ramamoorthy A,
    10. Desta Z, et al.
    (2014) Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet 10:e1004648.
    OpenUrl
    1. Smutny T and
    2. Pavek P.
    Resveratrol as an inhibitor of pregnane X receptor (P XR): another lesson in P XR antagonism. J Pharmacol Sci. 2014;126(2):177–8.
    OpenUrl
  142. ↵
    1. Souidi M,
    2. Gueguen Y,
    3. Linard C,
    4. Dudoignon N,
    5. Grison S,
    6. Baudelin C,
    7. Marquette C,
    8. Gourmelon P,
    9. Aigueperse J, and
    10. Dublineau I
    (2005) In vivo effects of chronic contamination with depleted uranium on CYP3A and associated nuclear receptors PXR and CAR in the rat. Toxicology 214:113–122.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Spruiell K,
    2. Jones DZ,
    3. Cullen JM,
    4. Awumey EM,
    5. Gonzalez FJ, and
    6. Gyamfi MA
    (2014a) Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice. Biochem Pharmacol 89:399–412.
    OpenUrlCrossRefPubMed
  144. ↵
    1. Spruiell K,
    2. Richardson RM,
    3. Cullen JM,
    4. Awumey EM,
    5. Gonzalez FJ, and
    6. Gyamfi MA
    (2014b) Role of pregnane X receptor in obesity and glucose homeostasis in male mice. J Biol Chem 289:3244–3261.
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Staudinger JL,
    2. Goodwin B,
    3. Jones SA,
    4. Hawkins-Brown D,
    5. MacKenzie KI,
    6. LaTour A,
    7. Liu Y,
    8. Klaassen CD,
    9. Brown KK,
    10. Reinhard J, et al.
    (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369–3374.
    OpenUrlAbstract/FREE Full Text
    1. Staudinger JL,
    2. Goodwin B,
    3. Jones SA,
    4. Hawkins-Brown D,
    5. MacKenzie KI,
    6. LaTour A,
    7. Liu Y,
    8. Klaassen CD,
    9. Brown KK,
    10. Reinhard J,
    11. Willson T M,
    12. Koller BH, and
    13. Kliewer SA.
    The nuclear receptor P XR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369–74.
    OpenUrlAbstract/FREE Full Text
  146. ↵
    1. Sueyoshi T,
    2. Li L,
    3. Wang H,
    4. Moore R,
    5. Kodavanti PR,
    6. Lehmler HJ,
    7. Negishi M, and
    8. Birnbaum LS
    (2014) Flame retardant BDE-47 effectively activates nuclear receptor CAR in human primary hepatocytes. Toxicol Sci 137:292–302.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Sui Y,
    2. Ai N,
    3. Park SH,
    4. Rios-Pilier J,
    5. Perkins JT,
    6. Welsh WJ, and
    7. Zhou C
    (2012) Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect 120:399–405.
    OpenUrlCrossRefPubMed
  148. ↵
    1. Sultana H,
    2. Watanabe K,
    3. Rana MM,
    4. Takashima R,
    5. Ohashi A,
    6. Komai M, and
    7. Shirakawa H
    (2018) Effects of vitamin K2 on the expression of genes involved in bile acid synthesis and glucose homeostasis in mice with humanized PXR. Nutrients 10:982.
    OpenUrl
  149. ↵
    1. Synold TW,
    2. Dussault I, and
    3. Forman BM
    (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584–590.
    OpenUrlCrossRefPubMed
  150. ↵
    1. Tabb MM,
    2. Sun A,
    3. Zhou C,
    4. Grün F,
    5. Errandi J,
    6. Romero K,
    7. Pham H,
    8. Inoue S,
    9. Mallick S,
    10. Lin M, et al.
    (2003) Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919–43927.
    OpenUrlAbstract/FREE Full Text
  151. ↵
    1. Takeshita A,
    2. Taguchi M,
    3. Koibuchi N, and
    4. Ozawa Y
    (2002) Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277:32453–32458.
    OpenUrlAbstract/FREE Full Text
    1. Tamasi V,
    2. Juvan P,
    3. Beer M,
    4. Rozman D, and
    5. Meyer UA.
    Transcriptional activation of P PARalpha by phenobarbital in the absence of CAR and P XR. Mol Pharm. 2009 Sep-Oct;6(5):1573–81.
    OpenUrlCrossRefPubMed
  152. ↵
    1. Tanaka E
    (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339–346.
    OpenUrlCrossRefPubMed
  153. ↵
    1. Teotico DG,
    2. Frazier ML,
    3. Ding F,
    4. Dokholyan NV,
    5. Temple BR, and
    6. Redinbo MR
    (2008) Active nuclear receptors exhibit highly correlated AF-2 domain motions. PLOS Comput Biol 4:e1000111.
    OpenUrlCrossRefPubMed
  154. ↵
    1. Tirona RG,
    2. Lee W,
    3. Leake BF,
    4. Lan LB,
    5. Cline CB,
    6. Lamba V,
    7. Parviz F,
    8. Duncan SA,
    9. Inoue Y,
    10. Gonzalez FJ, et al.
    (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220–224.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Toda T,
    2. Ohi K,
    3. Kudo T,
    4. Yoshida T,
    5. Ikarashi N,
    6. Ito K, and
    7. Sugiyama K
    (2009a) Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora. Drug Metab Pharmacokinet 24:201–208.
    OpenUrlCrossRefPubMed
  156. ↵
    1. Toda T,
    2. Saito N,
    3. Ikarashi N,
    4. Ito K,
    5. Yamamoto M,
    6. Ishige A,
    7. Watanabe K, and
    8. Sugiyama K
    (2009b) Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica 39:323–334.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Turnbaugh PJ,
    2. Ley RE,
    3. Mahowald MA,
    4. Magrini V,
    5. Mardis ER, and
    6. Gordon JI
    (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031.
    OpenUrlCrossRefPubMed
  158. ↵
    1. Uppal H,
    2. Toma D,
    3. Saini SP,
    4. Ren S,
    5. Jones TJ, and
    6. Xie W
    (2005) Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41:168–176.
    OpenUrlCrossRefPubMed
  159. ↵
    1. van Giersbergen PL,
    2. Gnerre C,
    3. Treiber A,
    4. Dingemanse J, and
    5. Meyer UA
    (2002) Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 450:115–121.
    OpenUrlCrossRefPubMed
  160. ↵
    1. Venkatesh M,
    2. Mukherjee S,
    3. Wang H,
    4. Li H,
    5. Sun K,
    6. Benechet AP,
    7. Qiu Z,
    8. Maher L,
    9. Redinbo MR,
    10. Phillips RS, et al.
    (2014) Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity 41:296–310.
    OpenUrlCrossRefPubMed
    1. Vyhlídalová B,
    2. Bartonková I,
    3. Jiskrová E,
    4. Li H,
    5. Mani S, and
    6. Dvorák Z.
    Differential activation of human pregnane X receptor P XR by isomeric mono-methylated indoles in intestinal and hepatic in vitro models. Toxicol Lett. 2020 May 15;324:104–110.
    OpenUrl
    1. Wahlang B,
    2. Falkner KC,
    3. Clair HB,
    4. Al-Eryani L,
    5. Prough RA,
    6. States JC,
    7. Coslo DM,
    8. Omiecinski CJ, and
    9. Cave MC.
    Human receptor activation by aroclor 1260, a polychlorinated biphenyl mixture. Toxicol Sci. 2014 Aug 1;140(2):283–97.
    OpenUrlCrossRefPubMed
  161. ↵
    1. Wahlang B,
    2. Alexander NC II.,
    3. Li X,
    4. Rouchka EC,
    5. Kirpich IA, and
    6. Cave MC
    (2021) Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis. Toxicol Rep 8:536–547.
    OpenUrl
    1. Wistuba W,
    2. Gnewuch C,
    3. Liebisch G,
    4. Schmitz G, and
    5. Langmann T.
    Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by P XR. World J Gastroenterol. 2007 Aug 21;13(31):4230–5.
    OpenUrlPubMed
  162. ↵
    1. Wahlang B,
    2. Jin J,
    3. Hardesty JE,
    4. Head KZ,
    5. Shi H,
    6. Falkner KC,
    7. Prough RA,
    8. Klinge CM, and
    9. Cave MC
    (2019) Identifying sex differences arising from polychlorinated biphenyl exposures in toxicant-associated liver disease. Food Chem Toxicol 129:64–76.
    OpenUrl
  163. ↵
    1. Wang DQ,
    2. Neuschwander-Tetri BA,
    3. Portincasa P, and
    4. Pandak WM
    (2012) Interactions between bile acids and nuclear receptors and their effects on lipid metabolism and liver diseases. J Lipids 2012:560715.
    OpenUrlPubMed
  164. ↵
    1. Wang H,
    2. Li H,
    3. Moore LB,
    4. Johnson MD,
    5. Maglich JM,
    6. Goodwin B,
    7. Ittoop OR,
    8. Wisely B,
    9. Creech K,
    10. Parks DJ, et al.
    (2008) The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 22:838–857.
    OpenUrlCrossRefPubMed
  165. ↵
    1. Wang H,
    2. Venkatesh M,
    3. Li H,
    4. Goetz R,
    5. Mukherjee S,
    6. Biswas A,
    7. Zhu L,
    8. Kaubisch A,
    9. Wang L,
    10. Pullman J, et al.
    (2011) Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest 121:3220–3232.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Wang JY,
    2. Tsai CH,
    3. Lee YL,
    4. Lee LN,
    5. Hsu CL,
    6. Chang HC,
    7. Chen JM,
    8. Hsu CA,
    9. Yu CJ, and
    10. Yang PC
    (2015) Gender-dimorphic impact of PXR genotype and haplotype on hepatotoxicity during antituberculosis treatment. Medicine (Baltimore) 94:e982.
    OpenUrl
  167. ↵
    1. Watkins RE,
    2. Maglich JM,
    3. Moore LB,
    4. Wisely GB,
    5. Noble SM,
    6. Davis-Searles PR,
    7. Lambert MH,
    8. Kliewer SA, and
    9. Redinbo MR
    (2003) 2.1 a crystal structure of human PXR in complex with the St. John’s wort compound hyperforin. Biochemistry 42:1430–1438.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Watkins RE,
    2. Wisely GB,
    3. Moore LB,
    4. Collins JL,
    5. Lambert MH,
    6. Williams SP,
    7. Willson TM,
    8. Kliewer SA, and
    9. Redinbo MR
    (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329–2333.
    OpenUrlAbstract/FREE Full Text
  169. ↵
    1. Weger BD,
    2. Gobet C,
    3. Yeung J,
    4. Martin E,
    5. Jimenez S,
    6. Betrisey B,
    7. Foata F,
    8. Berger B,
    9. Balvay A,
    10. Foussier A, et al.
    (2019) The mouse microbiome is required for sex-specific diurnal rhythms of gene expression and metabolism. Cell Metab 29:362–382.e8 10.1016/j.cmet.2018.09.023.
    OpenUrlCrossRef
  170. ↵
    1. Wei P,
    2. Zhang J,
    3. Dowhan DH,
    4. Han Y, and
    5. Moore DD
    (2002) Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2:117–126.
    OpenUrlCrossRefPubMed
    1. Zeng H,
    2. Jiang Y,
    3. Chen P,
    4. Fan X,
    5. Li D,
    6. Liu A,
    7. Ma X,
    8. Xie W,
    9. Liu P,
    10. Gonzalez FJ,
    11. Huang M, and
    12. Bi H.
    Schisandrol B protects against cholestatic liver injury through pregnane X receptors. Br J Pharmacol. 2017 Apr;174(8):672–688.
    OpenUrl
  171. ↵
    1. Wolbold R,
    2. Klein K,
    3. Burk O,
    4. Nüssler AK,
    5. Neuhaus P,
    6. Eichelbaum M,
    7. Schwab M, and
    8. Zanger UM
    (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978–988.
    OpenUrlCrossRefPubMed
  172. ↵
    1. Woolbright BL,
    2. Li F,
    3. Xie Y,
    4. Farhood A,
    5. Fickert P,
    6. Trauner M, and
    7. Jaeschke H
    (2014) Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. Toxicol Lett 228:56–66.
    OpenUrlCrossRefPubMed
  173. ↵
    1. Xiang D,
    2. Chu T,
    3. Li M,
    4. Wang Q, and
    5. Zhu G
    (2018) Effects of pyrethroid pesticide cis-bifenthrin on lipogenesis in hepatic cell line. Chemosphere 201:840–849.
    OpenUrl
  174. ↵
    1. Xiang J,
    2. Zhang Z,
    3. Xie H,
    4. Zhang C,
    5. Bai Y,
    6. Cao H,
    7. Che Q,
    8. Guo J, and
    9. Su Z
    (2021) Effect of different bile acids on the intestine through enterohepatic circulation based on FXR. Gut Microbes 13:1949095.
    OpenUrl
  175. ↵
    1. Xie W and
    2. Evans RM
    (2001) Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 276:37739–37742.
    OpenUrlFREE Full Text
  176. ↵
    1. Xie W,
    2. Radominska-Pandya A,
    3. Shi Y,
    4. Simon CM,
    5. Nelson MC,
    6. Ong ES,
    7. Waxman DJ, and
    8. Evans RM
    (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 98:3375–3380.
    OpenUrlAbstract/FREE Full Text
  177. ↵
    1. Xu DX,
    2. Chen YH,
    3. Wang JP,
    4. Sun MF,
    5. Wang H,
    6. Wei LZ, and
    7. Wei W
    (2005) Perinatal lipopolysaccharide exposure downregulates pregnane X receptor and Cyp3a11 expression in fetal mouse liver. Toxicol Sci 87:38–45.
    OpenUrlCrossRefPubMed
  178. ↵
    1. Xu DX,
    2. Wei W,
    3. Sun MF,
    4. Wu CY,
    5. Wang JP,
    6. Wei LZ, and
    7. Zhou CF
    (2004) Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. Free Radic Biol Med 37:10–22.
    OpenUrlCrossRefPubMed
  179. ↵
    1. Xu G,
    2. Dai M,
    3. Zheng X,
    4. Lin H,
    5. Liu A, and
    6. Yang J
    (2020) Cholestatic models induced by lithocholic acid and α-naphthylisothiocyanate: different etiological mechanisms for liver injury but shared JNK/STAT3 signaling. Mol Med Rep 22:1583–1593.
    OpenUrl
  180. ↵
    1. Yueh MF,
    2. Kawahara M, and
    3. Raucy J
    (2005) High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 33:38–48.
    OpenUrlAbstract/FREE Full Text
  181. ↵
    1. Zhang YK,
    2. Yeager RL, and
    3. Klaassen CD
    (2009) Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab Dispos 37:106–115.
    OpenUrlAbstract/FREE Full Text
  182. ↵
    1. Zhao LY,
    2. Xu JY,
    3. Shi Z,
    4. Englert NA, and
    5. Zhang SY
    (2017) Pregnane X receptor (PXR) deficiency improves high fat diet-induced obesity via induction of fibroblast growth factor 15 (FGF15) expression. Biochem Pharmacol 142:194–203.
    OpenUrlCrossRefPubMed
  183. ↵
    1. Zhou C,
    2. Poulton EJ,
    3. Grün F,
    4. Bammler TK,
    5. Blumberg B,
    6. Thummel KE, and
    7. Eaton DL
    (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229.
    OpenUrlAbstract/FREE Full Text
  184. ↵
    1. Zhou J,
    2. Febbraio M,
    3. Wada T,
    4. Zhai Y,
    5. Kuruba R,
    6. He J,
    7. Lee JH,
    8. Khadem S,
    9. Ren S,
    10. Li S, et al.
    (2008) Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 134:556–567.
    OpenUrlCrossRefPubMed
  185. ↵
    1. Zhou J,
    2. Zhai Y,
    3. Mu Y,
    4. Gong H,
    5. Uppal H,
    6. Toma D,
    7. Ren S,
    8. Evans RM, and
    9. Xie W
    (2006) A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 281:15013–15020.
    OpenUrlAbstract/FREE Full Text
  186. ↵
    1. Zhuo W,
    2. Hu L,
    3. Lv J,
    4. Wang H,
    5. Zhou H, and
    6. Fan L
    (2014) Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol 74:217–227.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (4)
Drug Metabolism and Disposition
Vol. 50, Issue 4
1 Apr 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pregnane X Receptor and the Gut-Liver Axis: A Recent Update
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section on Bile Acids, Drug Metabolism, and Toxicity

PXR and the Gut-Liver Axis

Moumita Dutta, Joe Jongpyo Lim and Julia Yue Cui
Drug Metabolism and Disposition April 1, 2022, 50 (4) 478-491; DOI: https://doi.org/10.1124/dmd.121.000415

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Section on Bile Acids, Drug Metabolism, and Toxicity

PXR and the Gut-Liver Axis

Moumita Dutta, Joe Jongpyo Lim and Julia Yue Cui
Drug Metabolism and Disposition April 1, 2022, 50 (4) 478-491; DOI: https://doi.org/10.1124/dmd.121.000415
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • PXR, Novel Endogenous PXR Activators, and the Gut Microbiome
    • Regulation of the Host PXR Signaling by Microbial Metabolite
    • Necessity of the Gut Microbiome in the Host PXR Signaling under Basal and Toxicological Conditions
    • Regulation of Gut Microbiome by PXR-Activating Xenobiotics
    • Regulation of Gut Microbiome by the Host PXR Gene under Basal and Pathophysiological Conditions
    • Modifying Factors of PXR-Signaling
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • ABBREVIATIONS
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Xenobiotics Modulate Bile Acids and FXR Pathway
  • Role of Nrf2 in Allergy
Show more Special Section on Bile Acids, Drug Metabolism, and Toxicity

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics